103 results on '"Blanco, P."'
Search Results
2. Newer generations of multi-target CAR and STAb-T immunotherapeutics: NEXT CART Consortium as a cooperative effort to overcome current limitations
- Author
-
Beatriz Martín-Antonio, Belén Blanco, África González-Murillo, Laura Hidalgo, Jordi Minguillón, Gema Pérez-Chacón, Next Generation CART MAD Consortium, Lucía Fernández, Halin Bareke, Andrés París-Muñoz, Adriana Mañas, Cristina Aguirre-Portolés, Alfonso Navarro-Zapata, Carmen Mestre-Durán, Marta Ibáñez-Navarro, Laura Clares-Villa, Sara Naharro, Antonio Perez-Martinez, Marcos Aldea, María Gaibar, Javier Ruiz-Navarro, Manuel Izquierdo, Juan M. Zapata, África González Murillo, Elena García Sánchez, Jorge García Martínez, Alba Rubio San Simón, Blanca Herrero, Gonzalo García Aguilera, Beatriz Horcajo Morera, Manuel Ramírez Orellana, Belén Blanco-Durango, Anais Jiménez-Reinoso, Rodrigo Lázaro-Gorines, Ivana Zagorac, Antonio Tapia Galisteo, Ángel Ramirez-Fernández, Laura Díez-Alonso, Carmen Dominguez-Alonso, Ainhoa Erce-Llamazares, Oana Hangiu, Laura Rubio Pérez, Marina Gómez Rosel, Alejandro Segura Tudela, Javier Arroyo-Ródena, Luis Álvarez-Vallina, Miguel Ángel Rodríguez Milla, Patricia García Rodríguez, Beatriz Somovilla Crespo, Javier García-Castro, Esperanza Esquinas Tarifa, Juana Serrano-López, Pilar Llamas-Sillero, and Beatriz Martin-Antonio
- Subjects
CAR-T cells ,NK cells ,TILs ,TCR therapy ,immunological synapse ,cancer ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Adoptive T cellular immunotherapies have emerged as relevant approaches for treating cancer patients who have relapsed or become refractory (R/R) to traditional cancer treatments. Chimeric antigen receptor (CAR) T-cell therapy has improved survival in various hematological malignancies. However, significant limitations still impede the widespread adoption of these therapies in most cancers. To advance in this field, six research groups have created the “NEXT Generation CART MAD Consortium” (NEXT CART) in Madrid’s Community, which aims to develop novel cell-based immunotherapies for R/R and poor prognosis cancers. At NEXT CART, various basic and translational research groups and hospitals in Madrid concur to share and synergize their basic expertise in immunotherapy, gene therapy, and immunological synapse, and clinical expertise in pediatric and adult oncology. NEXT CART goal is to develop new cell engineering approaches and treatments for R/R adult and pediatric neoplasms to evaluate in multicenter clinical trials. Here, we discuss the current limitations of T cell-based therapies and introduce our perspective on future developments. Advancement opportunities include developing allogeneic products, optimizing CAR signaling domains, combining cellular immunotherapies, multi-targeting strategies, and improving tumor-infiltrating lymphocytes (TILs)/T cell receptor (TCR) therapy. Furthermore, basic studies aim to identify novel tumor targets, tumor molecules in the tumor microenvironment that impact CAR efficacy, and strategies to enhance the efficiency of the immunological synapse between immune and tumor cells. Our perspective of current cellular immunotherapy underscores the potential of these treatments while acknowledging the existing hurdles that demand innovative solutions to develop their potential for cancer treatment fully.
- Published
- 2024
- Full Text
- View/download PDF
3. Systematic computer-aided disulfide design as a general strategy to stabilize prefusion class I fusion proteins
- Author
-
Karen J. Gonzalez, Kevin C. Yim, Jorge C. G. Blanco, Marina S. Boukhvalova, and Eva-Maria Strauch
- Subjects
vaccine development ,class I fusion proteins ,prefusion stabilization ,disulfide design ,computational modeling ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Numerous enveloped viruses, such as coronaviruses, influenza, and respiratory syncytial virus (RSV), utilize class I fusion proteins for cell entry. During this process, the proteins transition from a prefusion to a postfusion state, undergoing substantial and irreversible conformational changes. The prefusion conformation has repeatedly shown significant potential in vaccine development. However, the instability of this state poses challenges for its practical application in vaccines. While non-native disulfides have been effective in maintaining the prefusion structure, identifying stabilizing disulfide bonds remains an intricate task. Here, we present a general computational approach to systematically identify prefusion-stabilizing disulfides. Our method assesses the geometric constraints of disulfide bonds and introduces a ranking system to estimate their potential in stabilizing the prefusion conformation. We hypothesized that disulfides restricting the initial stages of the conformational switch could offer higher stability to the prefusion state than those preventing unfolding at a later stage. The implementation of our algorithm on the RSV F protein led to the discovery of prefusion-stabilizing disulfides that supported our hypothesis. Furthermore, the evaluation of our top design as a vaccine candidate in a cotton rat model demonstrated robust protection against RSV infection, highlighting the potential of our approach for vaccine development.
- Published
- 2024
- Full Text
- View/download PDF
4. ATP-P2X7R pathway activation limits the Tfh cell compartment during pediatric RSV infection
- Author
-
Constanza Russo, Silvina Raiden, Silvia Algieri, María José Bruera, Norberto De Carli, Mariam Sarli, Héctor Cairoli, Leonardo De Lillo, Ivanna Morales, Vanesa Seery, Adrián Otero, Inés Sananez, Nancy Simaz, Gisela Alfiero, Gabriela Rubino, Néstor Moya, Luisa Aedo Portela, Mauro Herrero, Marina Blanco, Misael Salcedo Pereira, Fernando Ferrero, Jorge Geffner, and Lourdes Arruvito
- Subjects
children ,RSV ,ATP ,Tfh cell ,antibodies ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundFollicular helper T cells (Tfh) are pivotal in B cell responses. Activation of the purinergic receptor P2X7 on Tfh cells regulates their activity. We investigated the ATP-P2X7R axis in circulating Tfh (cTfh) cells during Respiratory Syncytial Virus (RSV) infection.MethodsWe analyzed two cohorts: children with RSV infection (moderate, n=30; severe, n=21) and healthy children (n=23). We utilized ELISA to quantify the levels of PreF RSV protein-specific IgG antibodies, IL-21 cytokine, and soluble P2X7R (sP2X7R) in both plasma and nasopharyngeal aspirates (NPA). Additionally, luminometry was employed to determine ATP levels in plasma, NPA and supernatant culture. The frequency of cTfh cells, P2X7R expression, and plasmablasts were assessed by flow cytometry. To evaluate apoptosis, proliferation, and IL-21 production by cTfh cells, we cultured PBMCs in the presence of Bz-ATP and/or P2X7R antagonist (KN-62) and a flow cytometry analysis was performed.ResultsIn children with severe RSV disease, we observed diminished titers of neutralizing anti-PreF IgG antibodies. Additionally, severe infections, compared to moderate cases, were associated with fewer cTfh cells and reduced plasma levels of IL-21. Our investigation revealed dysregulation in the ATP-P2X7R pathway during RSV infection. This was characterized by elevated ATP levels in both plasma and NPA samples, increased expression of P2X7R on cTfh cells, lower levels of sP2X7R, and heightened ATP release from PBMCs upon stimulation, particularly evident in severe cases. Importantly, ATP exposure decreased cTfh proliferative response and IL-21 production, while promoting their apoptosis. The P2X7R antagonist KN-62 mitigated these effects. Furthermore, disease severity positively correlated with ATP levels in plasma and NPA samples and inversely correlated with cTfh frequency.ConclusionOur findings indicate that activation of the ATP-P2X7R pathway during RSV infection may contribute to limiting the cTfh cell compartment by promoting cell death and dysfunction, ultimately leading to increased disease severity.
- Published
- 2024
- Full Text
- View/download PDF
5. The role of probiotic therapy on clinical parameters and human immune response in peri-implant diseases: a systematic review and meta-analysis of randomized clinical studies
- Author
-
Nansi López-Valverde, Antonio López-Valverde, and José Antonio Blanco Rueda
- Subjects
probiotic ,prebiotic ,peri-implant disease ,mucositis ,peri-implantitis ,inmune-response ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundPeri-implant diseases (peri-implant mucositis and peri-implantitis) are pathologies of an infectious-inflammatory nature of the mucosa around dental implants. Probiotics are microorganisms that regulate host immunomodulation and have shown positive results in the treatment of peri-implant diseases. The objective of the systematic review and meta-analysis was to evaluate the efficacy of probiotics in the treatment of peri-implant oral diseases.MethodsAccording to the PRISMA guidelines, the research question was established: Are probiotics able to favorably modify clinical and immunological biomarkers determinants of peri-implant pathologies? and an electronic search of the databases MEDLINE/PubMed, Embase, Cochrane Central, Web of Science, (until December 2023) was performed. Inclusion criteria were established for intervention studies (RCTs), according to the PICOs strategy in subjects with peri-implant pathology (participants), treated with probiotics (intervention) compared to patients with conventional treatment or placebo (control) and evaluating the response to treatment (outcomes). Results- 1723 studies were obtained and 10 were selected. Risk of bias was assessed using the Cochrane Risk of Bias Tool and methodological quality using the Joanna Briggs Institute for RCTs. Two meta-analyses were performed, one to evaluate probiotics in mucositis and one for peri-implantitis. All subgroups were homogeneous (I2 = 0%), except in the analysis of IL-6 in mucositis (I2 = 65%). The overall effect was favorable to the experimental group in both pathologies. The analysis of the studies grouped in peri-implantitis showed a tendency to significance (p=0.09).ConclusionThe use of probiotics, as basic or complementary treatment of peri-implant diseases, showed a statistically significant trend, but well-designed studies are warranted to validate the efficacy of these products in peri-implant pathologies.
- Published
- 2024
- Full Text
- View/download PDF
6. Unraveling lipid and inflammation interplay in cancer, aging and infection for novel theranostic approaches
- Author
-
Daniel Conde-Torres, Alexandre Blanco-González, Alejandro Seco-González, Fabián Suárez-Lestón, Alfonso Cabezón, Paula Antelo-Riveiro, Ángel Piñeiro, and Rebeca García-Fandiño
- Subjects
cancer ,infection ,aging ,lipidomics ,chronic inflammation ,Immunologic diseases. Allergy ,RC581-607 - Abstract
The synergistic relationships between Cancer, Aging, and Infection, here referred to as the CAIn Triangle, are significant determinants in numerous health maladies and mortality rates. The CAIn-related pathologies exhibit close correlations with each other and share two common underlying factors: persistent inflammation and anomalous lipid concentration profiles in the membranes of affected cells. This study provides a comprehensive evaluation of the most pertinent interconnections within the CAIn Triangle, in addition to examining the relationship between chronic inflammation and specific lipidic compositions in cellular membranes. To tackle the CAIn-associated diseases, a suite of complementary strategies aimed at diagnosis, prevention, and treatment is proffered. Our holistic approach is expected to augment the understanding of the fundamental mechanisms underlying these diseases and highlight the potential of shared features to facilitate the development of novel theranostic strategies.
- Published
- 2024
- Full Text
- View/download PDF
7. Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant
- Author
-
Carlos Ávila-Nieto, Júlia Vergara-Alert, Pep Amengual-Rigo, Erola Ainsua-Enrich, Marco Brustolin, María Luisa Rodríguez de la Concepción, Núria Pedreño-Lopez, Jordi Rodon, Victor Urrea, Edwards Pradenas, Silvia Marfil, Ester Ballana, Eva Riveira-Muñoz, Mònica Pérez, Núria Roca, Ferran Tarrés-Freixas, Julieta Carabelli, Guillermo Cantero, Anna Pons-Grífols, Carla Rovirosa, Carmen Aguilar-Gurrieri, Raquel Ortiz, Ana Barajas, Benjamin Trinité, Rosalba Lepore, Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, Nuria Izquierdo-Useros, Alfonso Valencia, Julià Blanco, Bonaventura Clotet, Victor Guallar, Joaquim Segalés, and Jorge Carrillo
- Subjects
COVID-19 ,SARS-CoV-2 ,vaccine ,neutralizing antibodies ,humoral response ,Spike glycoprotein ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Most COVID-19 vaccines are based on the SARS-CoV-2 Spike glycoprotein (S) or their subunits. However, S shows some structural instability that limits its immunogenicity and production, hampering the development of recombinant S-based vaccines. The introduction of the K986P and V987P (S-2P) mutations increases the production and immunogenicity of the recombinant S trimer, suggesting that these two parameters are related. Nevertheless, S-2P still shows some molecular instability and it is produced with low yield. Here we described a novel set of mutations identified by molecular modeling and located in the S2 region of the S-2P that increase its production up to five-fold. Besides their immunogenicity, the efficacy of two representative S-2P-based mutants, S-29 and S-21, protecting from a heterologous SARS-CoV-2 Beta variant challenge was assayed in K18-hACE2 mice (an animal model of severe SARS-CoV-2 disease) and golden Syrian hamsters (GSH) (a moderate disease model). S-21 induced higher level of WH1 and Delta variants neutralizing antibodies than S-2P in K18-hACE2 mice three days after challenge. Viral load in nasal turbinate and oropharyngeal samples were reduced in S-21 and S-29 vaccinated mice. Despite that, only the S-29 protein protected 100% of K18-hACE2 mice from severe disease. When GSH were analyzed, all immunized animals were protected from disease development irrespectively of the immunogen they received. Therefore, the higher yield of S-29, as well as its improved immunogenicity and efficacy protecting from the highly pathogenic SARS-CoV-2 Beta variant, pinpoint the S-29 mutant as an alternative to the S-2P protein for future SARS-CoV-2 vaccine development.
- Published
- 2023
- Full Text
- View/download PDF
8. Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosus
- Author
-
Julius Lindblom, Lorenzo Beretta, Maria Orietta Borghi, PRECISESADS Clinical Consortium, Marta E. Alarcón-Riquelme, Ioannis Parodis, Barbara Vigone, Jacques-Olivier Pers, Alain Saraux, Valérie Devauchelle-Pensec, Divi Cornec, Sandrine Jousse-Joulin, Bernard Lauwerys, Julie Ducreux, Anne-Lise Maudoux, Carlos Vasconcelos, Ana Tavares, Esmeralda Neves, Raquel Faria, Mariana Brandão, Ana Campar, António Marinho, Farinha Fátima, Isabel Almeida, Angel Gonzalez-Gay Mantecón, Ricardo Blanco Alonso, Alfonso Corrales Martínez, Ricard Cervera, Ignasi Rodríguez-Pintó, Gerard Espinosa, Rik Lories, Ellen De Langhe, Nicolas Hunzelmann, Doreen Belz, Torsten Witte, Niklas Baerlecken, Georg Stummvoll, Michael Zauner, Michaela Lehner, Eduardo Collantes, Rafaela Ortega-Castro, MaAngeles Aguirre-Zamorano, Alejandro Escudero-Contreras, MaCarmen Castro-Villegas, Norberto Ortego, María Concepción Fernández Roldán, Enrique Raya, Inmaculada Jiménez Moleón, Enrique de Ramon, Isabel Díaz Quintero, Pier Luigi Meroni, Maria Gerosa, Tommaso Schioppo, Carolina Artusi, Carlo Chizzolini, Aleksandra Zuber, Donatienne Wynar, Laszló Kovács, Attila Balog, Magdolna Deák, Márta Bocskai, Sonja Dulic, Gabriella Kádár, Falk Hiepe, Velia Gerl, Silvia Thiel, Manuel Rodriguez Maresca, Antonio López-Berrio, Rocío Aguilar-Quesada, and Héctor Navarro-Linares.
- Subjects
autoimmunity ,systemic lupus erythematosus ,antiphospholipid syndrome ,diagnosis ,biomarkers ,cytokines ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionSystemic lupus erythematosus (SLE) is a clinically heterogeneous disease that presents a challenge for clinicians. To identify potential biomarkers for diagnosis and disease activity in SLE, we investigated a selected yet broad panel of cytokines and autoantibodies in patients with SLE, healthy controls (HC), and patients with other autoimmune diseases (AIDs).MethodsSerum samples from 422 SLE patients, 546 HC, and 1223 other AIDs were analysed within the frame of the European PRECISESADS project (NTC02890121). Cytokine levels were determined using Luminex panels, and autoantibodies using different immunoassays.ResultsOf the 83 cytokines analysed, 29 differed significantly between patients with SLE and HC. Specifically, CCL8, CXCL13, and IL-1RA levels were elevated in patients with active, but not inactive, SLE versus HC, as well as in patients with SLE versus other AIDs. The levels of these cytokines also correlated with SLE Disease Activity Index 2000 (SLEDAI-2K) scores, among five other cytokines. Overall, the occurrence of autoantibodies was similar across SLEDAI-2K organ domains, and the correlations between autoantibodies and activity in different organ domains were weak.DiscussionOur findings suggest that, upon validation, CCL8, CXCL13, and IL-1RA could serve as promising serum biomarkers of activity in SLE.
- Published
- 2023
- Full Text
- View/download PDF
9. Corrigendum: The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases
- Author
-
Victoria Navarro-Compán, Luis Puig, Silvia Vidal, Julio Ramírez, Mar Llamas-Velasco, Cristina Fernández-Carballido, Raquel Almodóvar, José Antonio Pinto, Eva Galíndez-Aguirregoikoa, Pedro Zarco, Beatriz Joven, Jordi Gratacós, Xavier Juanola, Ricardo Blanco, Salvador Arias-Santiago, Jesús Sanz Sanz, Rubén Queiro, and Juan D. Cañete
- Subjects
IL-17A ,IL-17F ,IL-23 ,spondyloarthritis ,Th17 cells ,MAIT cells ,Immunologic diseases. Allergy ,RC581-607 - Published
- 2023
- Full Text
- View/download PDF
10. Automated EuroFlow approach for standardized in-depth dissection of human circulating B-cells and plasma cells
- Author
-
Alejandro H. Delgado, Rafael Fluxa, Martin Perez-Andres, Annieck M. Diks, Jacqueline A. M. van Gaans-van den Brink, Alex-Mikael Barkoff, Elena Blanco, Alba Torres-Valle, Magdalena A. Berkowska, Georgiana Grigore, J .J .M. van Dongen, and Alberto Orfao
- Subjects
multiparameter flow cytometry ,automated gating and identification approach ,EuroFlow ,standardization ,B-cell ,plasma cell ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundMultiparameter flow cytometry (FC) immunophenotyping is a key tool for detailed identification and characterization of human blood leucocytes, including B-lymphocytes and plasma cells (PC). However, currently used conventional data analysis strategies require extensive expertise, are time consuming, and show limited reproducibility.ObjectiveHere, we designed, constructed and validated an automated database-guided gating and identification (AGI) approach for fast and standardized in-depth dissection of B-lymphocyte and PC populations in human blood.MethodsFor this purpose, 213 FC standard (FCS) datafiles corresponding to umbilical cord and peripheral blood samples from healthy and patient volunteers, stained with the 14-color 18-antibody EuroFlow BIgH-IMM panel, were used.ResultsThe BIgH-IMM antibody panel allowed identification of 117 different B-lymphocyte and PC subsets. Samples from 36 healthy donors were stained and 14 of the datafiles that fulfilled strict inclusion criteria were analysed by an expert flow cytometrist to build the EuroFlow BIgH-IMM database. Data contained in the datafiles was then merged into a reference database that was uploaded in the Infinicyt software (Cytognos, Salamanca, Spain). Subsequently, we compared the results of manual gating (MG) with the performance of two classification algorithms -hierarchical algorithm vs two-step algorithm- for AGI of the cell populations present in 5 randomly selected FCS datafiles. The hierarchical AGI algorithm showed higher correlation values vs conventional MG (r2 of 0.94 vs. 0.88 for the two-step AGI algorithm) and was further validated in a set of 177 FCS datafiles against conventional expert-based MG. For virtually all identifiable cell populations a highly significant correlation was observed between the two approaches (r2>0.81 for 79% of all B-cell populations identified), with a significantly lower median time of analysis per sample (6 vs. 40 min, p=0.001) for the AGI tool vs. MG, respectively and both intra-sample (median CV of 1.7% vs. 10.4% by MG, p
- Published
- 2023
- Full Text
- View/download PDF
11. Editorial: Mitochondrial dysfunction in inflammation and autoimmunity
- Author
-
Jens Staal, Luz Pamela Blanco, and Andras Perl
- Subjects
inflammation ,mitochondria ,autoimmune diseases ,ferroptosis ,interferonopathy ,metabolism ,Immunologic diseases. Allergy ,RC581-607 - Published
- 2023
- Full Text
- View/download PDF
12. Increased gut permeability and bacterial translocation are associated with fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome: implications for disease-related biomarker discovery
- Author
-
Franz Martín, Manuel Blanco-Suárez, Paola Zambrano, Oscar Cáceres, Miriam Almirall, José Alegre-Martín, Beatriz Lobo, Ana Maria González-Castro, Javier Santos, Joan Carles Domingo, Joanna Jurek, and Jesús Castro-Marrero
- Subjects
anti-beta-lactoglobulin ,chronic fatigue syndrome ,fibromyalgia ,intestinal permeability ,myalgic encephalomyelitis ,zonulin ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundThere is growing evidence of the significance of gastrointestinal complaints in the impairment of the intestinal mucosal barrier function and inflammation in fibromyalgia (FM) and in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). However, data on intestinal permeability and gut barrier dysfunction in FM and ME/CFS are still limited with conflicting results. This study aimed to assess circulating biomarkers potentially related to intestinal barrier dysfunction and bacterial translocation and their association with self-reported symptoms in these conditions.MethodsA pilot multicenter, cross-sectional cohort study with consecutive enrolment of 22 patients with FM, 30 with ME/CFS and 26 matched healthy controls. Plasma levels of anti-beta-lactoglobulin antibodies (IgG anti-β-LGB), zonulin-1 (ZO-1), lipopolysaccharides (LPS), soluble CD14 (sCD14) and interleukin-1-beta (IL-1β) were assayed using ELISA. Demographic and clinical characteristics of the participants were recorded using validated self-reported outcome measures. The diagnostic accuracy of each biomarker was assessed using the receiver operating characteristic (ROC) curve analysis.ResultsFM patients had significantly higher levels of anti-β-LGB, ZO-1, LPS, and sCD14 than healthy controls (all P < 0.0001). In ME/CFS patients, levels of anti-β-LGB, ZO-1, LPS, and sCD14 were significantly higher than controls, but lower than in FM (all P < 0.01), while there was no significant difference in IL-1β level. In the FM and ME/CFS cohorts, both anti-β-LGB and ZO-1 correlated significantly with LPS and sCD14 (P < 0.001 for both). In the FM group, both anti-β-LGB and ZO-1 were correlated significantly with physical and mental health components on the SF-36 scale (P < 0.05); whereas IL-1β negatively correlated with the COMPASS-31 score (P < 0.05). In the ME/CFS cohort, ZO-1 was positively correlated with the COMPASS-31 score (P < 0.05). The ROC curve analysis indicated a strong ability of anti-β-LGB, ZO-1, LPS and sCD14 to predictively distinguish between FM and ME/CFS from healthy controls (P < 0.0001).ConclusionBiomarkers of intestinal barrier function and inflammation were associated with autonomic dysfunction assessed by COMPASS-31 scores in FM and ME/CFS respectively. Anti-β-LGB antibodies, ZO-1, LPS, and sCD14 may be putative predictors of intestinal barrier dysfunction in these cohorts. Further studies are needed to assess whether these findings are causal and can therefore be applied in clinical practice.
- Published
- 2023
- Full Text
- View/download PDF
13. The complex HLA-E-nonapeptide in Behçet disease
- Author
-
Ángel Luís Castaño-Núñez, Marco-Antonio Montes-Cano, José-Raúl García-Lozano, Norberto Ortego-Centeno, Francisco José García-Hernández, Gerard Espinosa, Genaro Graña-Gil, Juan Sánchez-Bursón, María Rosa Juliá, Roser Solans, Ricardo Blanco, Ana-Celia Barnosi-Marín, Ricardo Gómez de la Torre, Patricia Fanlo, Mónica Rodríguez-Carballeira, Luis Rodríguez-Rodríguez, Teresa Camps, Santos Castañeda, Juan-Jose Alegre-Sancho, Javier Martín, and María Francisca González-Escribano
- Subjects
Behçet disease ,gene association ,classical HLA Class I molecules ,HLA-E ,NK cells ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionThe knowledge of the aetiology of Behçet disease (BD), an immune-mediated vasculitis, is limited. HLA-B, mainly HLA-B51, and HLA-A molecules are associated with disease, but the ultimate cause of this association remains obscure. There is evidence that NK cells participate in the etiopathology of BD. NK cells have activator and inhibitor surface receptors, like the KIR and the NKG2 families. Classical HLA-class I molecules (A, B and C) are keys in the activity control of the NK because they are KIR ligands. Most NKG2 receptors bind HLA-E, which presents only nonapeptides derived from the signal peptide of other class-I molecules.ObjectiveThis study investigates the contribution of the pair HLA-E and ligand, nonapeptide derived from the 3-11 sequence of the signal peptides of class I classical molecules, to the susceptibility to BD.MethodsWe analyzed the frequency of the HLA-derivated nonapeptide forms in 466 BD patients and 444 controls and an HLA-E functional dimorphism in a subgroup of patients and controls. Results: In B51 negative patients, the frequency of VMAPRTLLL was lower (70.4% versus 80.0% in controls; P=0.006, Pc=0.04, OR=0.60, 95%CI 0.41-0.86), and the frequency of VMAPRTLVL was higher (81.6% versus 71.4% in controls; P=0.004, Pc=0.03, OR=1.78, 95%CI 1.20-2.63). In homozygosity, VMAPRTLLL is protective, and VMAPRTLVL confers risk. The heterozygous condition is neutral. There were no significant differences in the distribution of the HLA-E dimorphism.DiscussionOur results explain the association of BD with diverse HLA-A molecules, reinforce the hypothesis of the involvement of the NK cells in the disease and do not suggest a significant contribution of the HLA-E polymorphism to disease susceptibility.
- Published
- 2023
- Full Text
- View/download PDF
14. The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases
- Author
-
Victoria Navarro-Compán, Luis Puig, Silvia Vidal, Julio Ramírez, Mar Llamas-Velasco, Cristina Fernández-Carballido, Raquel Almodóvar, José Antonio Pinto, Eva Galíndez-Aguirregoikoa, Pedro Zarco, Beatriz Joven, Jordi Gratacós, Xavier Juanola, Ricardo Blanco, Salvador Arias-Santiago, Jesús Sanz Sanz, Rubén Queiro, and Juan D. Cañete
- Subjects
IL-17A ,IL-17F ,IL-23 ,spondyloarthritis ,Th17 cells ,MAIT cells ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Interleukin-17 family (IL-17s) comprises six structurally related members (IL-17A to IL-17F); sequence homology is highest between IL-17A and IL-17F, displaying certain overlapping functions. In general, IL-17A and IL-17F play important roles in chronic inflammation and autoimmunity, controlling bacterial and fungal infections, and signaling mainly through activation of the nuclear factor-kappa B (NF-κB) pathway. The role of IL-17A and IL-17F has been established in chronic immune-mediated inflammatory diseases (IMIDs), such as psoriasis (PsO), psoriatic arthritis (PsA), axial spondylarthritis (axSpA), hidradenitis suppurativa (HS), inflammatory bowel disease (IBD), multiple sclerosis (MS), and asthma. CD4+ helper T cells (Th17) activated by IL-23 are well-studied sources of IL-17A and IL-17F. However, other cellular subtypes can also produce IL-17A and IL-17F, including gamma delta (γδ) T cells, alpha beta (αβ) T cells, type 3 innate lymphoid cells (ILC3), natural killer T cells (NKT), or mucosal associated invariant T cells (MAIT). Interestingly, the production of IL-17A and IL-17F by innate and innate-like lymphocytes can take place in an IL-23 independent manner in addition to IL-23 classical pathway. This would explain the limitations of the inhibition of IL-23 in the treatment of patients with certain rheumatic immune-mediated conditions such as axSpA. Despite their coincident functions, IL-17A and IL-17F contribute independently to chronic tissue inflammation having somehow non-redundant roles. Although IL-17A has been more widely studied, both IL-17A and IL-17F are overexpressed in PsO, PsA, axSpA and HS. Therefore, dual inhibition of IL-17A and IL-17F could provide better outcomes than IL-23 or IL-17A blockade.
- Published
- 2023
- Full Text
- View/download PDF
15. Interleukin-17–targeted treatment in patients with spondyloarthritis and associated cardiometabolic risk profile
- Author
-
Rubén Queiro, Elena Aurrecoechea, Sara Alonso Castro, Ignacio Villa Blanco, Anahy Brandy-Garcia, and Raquel Linge
- Subjects
biologic therapy ,cardiometabolic comorbidities ,interleukin-17A ,metabolic syndrome ,obesity ,secukinumab ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Spondyloarthritis is a group of immune-mediated rheumatic disorders that significantly impact patients’ physical function and quality of life. Patients with spondyloarthritis experience a greater prevalence of cardiometabolic disorders, such as obesity, hypertension, dyslipidemia and diabetes mellitus, and these comorbidities are associated with increased spondyloarthritis disease activity and risk of cardiovascular events. This narrative review summarizes the evidence for a physiological link between inflammatory status and cardiometabolic comorbidities in spondyloarthritis, as well as the impact of interleukin (IL)-17 blockade versus other molecular mechanisms in patients with cardiometabolic conditions. The IL-23/IL-17 axis plays a pivotal role in the pathophysiology of spondyloarthritis by promoting inflammation and tissue remodeling at the affected joints and entheses. The importance of the IL-23/IL-17 signaling cascade in underlying sub-clinical inflammation in common cardiometabolic disorders suggests the existence of shared pathways between these processes and spondyloarthritis pathophysiology. Thus, a bidirectional relationship exists between the effects of biologic drugs and patients’ cardiometabolic profile, which must be considered during treatment decision making. Biologic therapy may induce changes in patients’ cardiometabolic status and cardiometabolic conditions may conversely impact the clinical response to biologic therapy. Available evidence regarding the impact of IL-17 blockade with secukinumab on cardiometabolic parameters suggests this drug does not interfere with traditional cardiovascular risk markers and could be associated with a decreased risk of cardiovascular events. Additionally, the efficacy and retention rates of secukinumab do not appear to be negatively affected by obesity, with some studies reporting a positive impact on clinical outcomes, contrary to that described with other approaches, such as tumor necrosis factor blockade. In this article, we also review evidence for this bidirectional association with other treatments for spondyloarthritis. Current evidence suggests that IL-17–targeted therapy with secukinumab is highly effective in spondyloarthritis patients with cardiometabolic comorbidities and may provide additional cardiometabolic benefits.
- Published
- 2023
- Full Text
- View/download PDF
16. Management of eosinophil-associated inflammatory diseases: the importance of a multidisciplinary approach
- Author
-
Santiago Quirce, Borja G. Cosío, Agustín España, Ricardo Blanco, Joaquim Mullol, Cecilio Santander, and Victoria del Pozo
- Subjects
eosinophil ,eosinophilic inflammation ,eosinophil-associated disease ,multidisciplinary management ,expert opinion ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Elevated eosinophil counts in blood and tissue are a feature of many pathological processes. Eosinophils can migrate and accumulate in a wide variety of tissues and, by infiltrating a target organ, can mediate the development of several inflammatory diseases. The normalization of eosinophilia is a common biomarker of a treatable trait and can also be used as a prognostic and predictive biomarker since it implies a reduction in type 2 inflammation that contributes to disease pathogenesis. Biological therapies targeting this cell type and its proinflammatory mediators have been shown to be effective in the management of a number of eosinophilic diseases, and for this reason they constitute a potential common strategy in the treatment of patients with various multimorbidities that present with type 2 inflammation. Various biological options are available that could be used to simultaneously treat multiple target organs with a single drug, bearing in mind the need to offer personalized treatments under the umbrella of precision medicine in all patients with eosinophil-associated diseases (EADs). In addition to reviewing these issues, we also discuss a series of perspectives addressing the management of EAD patients from a multidisciplinary approach, with the collaboration of health professionals from different specialties who manage the different multimorbidities that frequently occur in these patients. We examine the basic principles of care that this multidisciplinary approach must cover and present a multidisciplinary expert opinion regarding the ideal management of patients with EADs, from diagnosis to therapeutic approach and follow-up.
- Published
- 2023
- Full Text
- View/download PDF
17. Syphilis vaccine: challenges, controversies and opportunities
- Author
-
Carlos Ávila-Nieto, Núria Pedreño-López, Oriol Mitjà, Bonaventura Clotet, Julià Blanco, and Jorge Carrillo
- Subjects
syphilis ,treponema pallidum ,vaccine ,immune response ,outer membrane proteins ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Syphilis is a sexually or vertically (mother to fetus) transmitted disease caused by the infection of Treponema pallidum subspecie pallidum (TPA). The incidence of syphilis has increased over the past years despite the fact that this bacterium is an obligate human pathogen, the infection route is well known, and the disease can be successfully treated with penicillin. As complementary measures to preventive campaigns and early treatment of infected individuals, development of a syphilis vaccine may be crucial for controlling disease spread and/or severity, particularly in countries where the effectiveness of the aforementioned measures is limited. In the last century, several vaccine prototypes have been tested in preclinical studies, mainly in rabbits. While none of them provided protection against infection, some prototypes prevented bacteria from disseminating to distal organs, attenuated lesion development, and accelerated their healing. In spite of these promising results, there is still some controversy regarding the identification of vaccine candidates and the characteristics of a syphilis-protective immune response. In this review, we describe what is known about TPA immune response, and the main mechanisms used by this pathogen to evade it. Moreover, we emphasize the importance of integrating this knowledge, in conjunction with the characterization of outer membrane proteins (OMPs), to expedite the development of a syphilis vaccine that can protect against TPA infection.
- Published
- 2023
- Full Text
- View/download PDF
18. Pleiotropic antifibrotic actions of aspirin-triggered resolvin D1 in the lungs
- Author
-
Rafael F. Guilherme, José Bruno N.F. Silva, Ingrid Waclawiack, Vanderlei S. Fraga-Junior, Thaís O. Nogueira, Cyntia Pecli, Carlla A. Araújo-Silva, Nathalia S. Magalhães, Felipe S. Lemos, Carlos A. Bulant, Pablo J. Blanco, Rafaela Serra, Erik Svensjö, Júlio Scharfstein, João A. Moraes, Claudio Canetti, and Claudia F. Benjamim
- Subjects
ATRvD1 ,lung ,inflammation ,fibrosis ,macrophages ,angiogenesis ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionPulmonary fibrosis is a destructive, progressive disease that dramatically reduces life quality of patients, ultimately leading to death. Therapeutic regimens for pulmonary fibrosis have shown limited benefits, hence justifying the efforts to evaluate the outcome of alternative treatments.MethodsUsing a mouse model of bleomycin (BLM)-induced lung fibrosis, in the current work we asked whether treatment with pro-resolution molecules, such as pro-resolving lipid mediators (SPMs) could ameliorate pulmonary fibrosis. To this end, we injected aspirin-triggered resolvin D1 (7S,8R,17R-trihydroxy-4Z,9E,11E,13Z,15E19Z-docosahexaenoic acid; ATRvD1; i.v.) 7 and 10 days after BLM (intratracheal) challenge and samples were two weeks later.Results and discussionAssessment of outcome in the lung tissues revealed that ATRvD1 partially restored lung architecture, reduced leukocyte infiltration, and inhibited formation of interstitial edema. In addition, lung tissues from BLM-induced mice treated with ATRvD1 displayed reduced levels of TNF-α, MCP-1, IL-1-β, and TGF-β. Of further interest, ATRvD1 decreased lung tissue expression of MMP-9, without affecting TIMP-1. Highlighting the beneficial effects of ATRvD1, we found reduced deposition of collagen and fibronectin in the lung tissues. Congruent with the anti-fibrotic effects that ATRvD1 exerted in lung tissues, α-SMA expression was decreased, suggesting that myofibroblast differentiation was inhibited by ATRvD1. Turning to culture systems, we next showed that ATRvD1 impaired TGF-β-induced fibroblast differentiation into myofibroblast. After showing that ATRvD1 hampered extracellular vesicles (EVs) release in the supernatants from TGF-β-stimulated cultures of mouse macrophages, we verified that ATRvD1 also inhibited the release of EVs in the bronco-alveolar lavage (BAL) fluid of BLM-induced mice. Motivated by studies showing that BLM-induced lung fibrosis is linked to angiogenesis, we asked whether ATRvD1 could blunt BLM-induced angiogenesis in the hamster cheek pouch model (HCP). Indeed, our intravital microscopy studies confirmed that ATRvD1 abrogates BLM-induced angiogenesis. Collectively, our findings suggest that treatment of pulmonary fibrosis patients with ATRvD1 deserves to be explored as a therapeutic option in the clinical setting.
- Published
- 2023
- Full Text
- View/download PDF
19. Factors associated with the humoral response after three doses of COVID-19 vaccination in kidney transplant recipients
- Author
-
Ángel Bulnes-Ramos, María Mar Pozo-Balado, Israel Olivas-Martínez, Vanesa Garrido-Rodríguez, Gabriel Bernal-Blanco, Alejandro Suárez-Benjumea, Ana Isabel Álvarez-Ríos, Carmen Lozano, Carmen González-Corvillo, Marta Suñer-Poblet, Francisco Manuel González-Roncero, Berta Sánchez, Isabel Maldonado-Calzado, José Manuel Lara-Ruiz, María Francisca Gonzalez-Escribano, and Yolanda María Pacheco
- Subjects
COVID-19 ,kidney transplant ,mRNA vaccine ,relative telomere length ,thymic function ,thymosin-α1 ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionKidney transplant recipients showed a weak humoral response to the mRNA COVID-19 vaccine despite receiving three cumulative doses of the vaccine. New approaches are still needed to raise protective immunity conferred by the vaccine administration within this group of high-risk patients. MethodsTo analyze the humoral response and identify any predictive factors within these patients, we designed a prospective monocentric longitudinal study of Kidney transplant recipients (KTR) who received three doses of mRNA-1273 COVID-19 vaccine. Specific antibody levels were measured by chemiluminescence. Parameters related to clinical status such as kidney function, immunosuppressive therapy, inflammatory status and thymic function were analyzed as potential predictors of the humoral response. ResultsSeventy-four KTR and sixteen healthy controls were included. One month after the administration of the third dose of the COVID-19 vaccine, 64.8% of KTR showed a positive humoral response. As predictive factors of seroconversion and specific antibody titer, we found that immunosuppressive therapy, worse kidney function, higher inflammatory status and age were related to a lower response in KTR while immune cell counts, thymosin-a1 plasma concentration and thymic output were related to a higher humoral response. Furthermore, baseline thymosin-a1 concentration was independently associated with the seroconversion after three vaccine doses. DiscussionIn addition to the immunosuppression therapy, condition of kidney function and age before vaccination, specific immune factors could also be relevant in light of optimization of the COVID-19 vaccination protocol in KTR. Therefore, thymosin-a1, an immunomodulatory hormone, deserves further research as a potential adjuvant for the next vaccine boosters.
- Published
- 2023
- Full Text
- View/download PDF
20. Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors
- Author
-
Athina Kilpeläinen, Esther Jimenez-Moyano, Oscar Blanch-Lombarte, Dan Ouchi, Ruth Peña, Bibiana Quirant-Sanchez, Raul Perez-Caballero, Anna Chamorro, Ignacio Blanco, Eva Martínez-Caceres, Roger Paredes, Lourdes Mateu, Jorge Carrillo, Julià Blanco, Christian Brander, Marta Massanella, Bonaventura Clotet, and Julia G. Prado
- Subjects
SARS-CoV-2 ,non-seroconvertor ,cellular immunity ,T cell subsets ,immune activation ,function ,Immunologic diseases. Allergy ,RC581-607 - Abstract
The role of T cells in the control of SARS-CoV-2 infection has been underestimated in favor of neutralizing antibodies. However, cellular immunity is essential for long-term viral control and protection from disease severity. To understand T-cell immunity in the absence of antibody generation we focused on a group of SARS-CoV-2 Non-Seroconvertors (NSC) recovered from infection. We performed an immune comparative analysis of SARS-CoV-2 infected individuals stratified by the absence or presence of seroconversion and disease severity. We report high levels of total naïve and low effector CD8+ T cells in NSC. Moreover, reduced levels of T-cell activation monitored by PD-1 and activation-induced markers were observed in the context of functional SARS-CoV-2 T-cell responses. Longitudinal data indicate the stability of the NSC phenotype over three months of follow-up after infection. Together, these data characterized distinctive immunological traits in NSC including skewed cellular distribution, low activation and functional SARS-CoV-2 T-cell responses. This data highlights the value of T-cell immune monitoring in populations with low seroconversion rates in response to SARS-CoV-2 infection and vaccination.
- Published
- 2022
- Full Text
- View/download PDF
21. In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant
- Author
-
Natalie Heinen, Corinna Sophie Marheinecke, Clara Bessen, Arturo Blazquez-Navarro, Toralf Roch, Ulrik Stervbo, Moritz Anft, Carlos Plaza-Sirvent, Sandra Busse, Mara Klöhn, Jil Schrader, Elena Vidal Blanco, Doris Urlaub, Carsten Watzl, Markus Hoffmann, Stefan Pöhlmann, Matthias Tenbusch, Eike Steinmann, Daniel Todt, Carsten Hagenbeck, Gert Zimmer, Wolfgang Ekkehard Schmidt, Daniel Robert Quast, Nina Babel, Ingo Schmitz, and Stephanie Pfänder
- Subjects
COVID-19 ,vaccine ,immunity ,SARS-CoV-2 ,omicron ,Immunologic diseases. Allergy ,RC581-607 - Abstract
With the emergence of novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Variants of Concern (VOCs), vaccination studies that elucidate the efficiency and effectiveness of a vaccination campaign are critical to assess the durability and the protective immunity provided by vaccines. SARS-CoV-2 vaccines have been found to induce robust humoral and cell-mediated immunity in individuals vaccinated with homologous vaccination regimens. Recent studies also suggest improved immune response against SARS-CoV-2 when heterologous vaccination strategies are employed. Yet, few data exist on the extent to which heterologous prime-boost-boost vaccinations with two different vaccine platforms have an impact on the T cell-mediated immune responses with a special emphasis on the currently dominantly circulating Omicron strain. In this study, we collected serum and peripheral blood mononuclear cells (PBMCs) from 57 study participants of median 35-year old’s working in the health care field, who have received different vaccination regimens. Neutralization assays revealed robust but decreased neutralization of Omicron VOC, including BA.1 and BA.4/5, compared to WT SARS-CoV-2 in all vaccine groups and increased WT SARS-CoV-2 binding and neutralizing antibodies titers in homologous mRNA prime-boost-boost study participants. By investigating cytokine production, we found that homologous and heterologous prime-boost-boost-vaccination induces a robust cytokine response of CD4+ and CD8+ T cells. Collectively, our results indicate robust humoral and T cell mediated immunity against Omicron in homologous and heterologous prime-boost-boost vaccinated study participants, which might serve as a guide for policy decisions.
- Published
- 2022
- Full Text
- View/download PDF
22. Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIV
- Author
-
Clara Bessen, Carlos Plaza-Sirvent, Agit Simsek, Jaydeep Bhat, Corinna Marheinecke, Doris Urlaub, Petra Bonowitz, Sandra Busse, Sabrina Schumann, Elena Vidal Blanco, Adriane Skaletz-Rorowski, Norbert H. Brockmeyer, Oliver Overheu, Anke Reinacher-Schick, Simon Faissner, Carsten Watzl, Stephanie Pfaender, Anja Potthoff, and Ingo Schmitz
- Subjects
SARS-CoV-2 ,mRNA vaccine ,HIV ,immunodeficiency ,antibody ,T cells ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Despite the development of vaccines, which protect healthy people from severe and life-threatening Covid-19, the immunological responses of people with secondary immunodeficiencies to these vaccines remain incompletely understood. Here, we investigated the humoral and cellular immune responses elicited by mRNA-based SARS-CoV-2 vaccines in a cohort of people living with HIV (PLWH) receiving anti-retroviral therapy. While antibody responses in PLWH increased progressively after each vaccination, they were significantly reduced compared to the HIV-negative control group. This was particularly noteworthy for the Delta and Omicron variants. In contrast, CD4+ Th cell responses exhibited a vaccination-dependent increase, which was comparable in both groups. Interestingly, CD4+ T cell activation negatively correlated with the CD4 to CD8 ratio, indicating that low CD4+ T cell numbers do not necessarily interfere with cellular immune responses. Our data demonstrate that despite the lower CD4+ T cell counts SARS-CoV-2 vaccination results in potent cellular immune responses in PLWH. However, the reduced humoral response also provides strong evidence to consider PLWH as vulnerable group and suggests subsequent vaccinations being required to enhance their protection against COVID-19.
- Published
- 2022
- Full Text
- View/download PDF
23. Extracellular vesicles from pristane-treated CD38-deficient mice express an anti-inflammatory neutrophil protein signature, which reflects the mild lupus severity elicited in these mice
- Author
-
Paula Carrillo-Rodríguez, José-Ángel Robles-Guirado, Adrián Cruz-Palomares, Miguel Ángel Palacios-Pedrero, Elena González-Paredes, Alex Más-Ciurana, Carolina Franco-Herrera, Paloma A. Ruiz-de-Castroviejo-Teba, Antonio Lario, Victoria Longobardo, Laura Montosa-Hidalgo, María M. Pérez-Sánchez-Cañete, María-Mercedes Corzo-Corbera, Sandra Redondo-Sánchez, Ana-Belén Jodar, Francisco J. Blanco, Esther Zumaquero, Ramón Merino, Jaime Sancho, and Mercedes Zubiaur
- Subjects
extracellular vesicles ,inflammation ,pro-resolving neutrophil-signature ,lupus ,CD38 ,annexin-1 ,Immunologic diseases. Allergy ,RC581-607 - Abstract
In CD38-deficient (Cd38-/-) mice intraperitoneal injection of pristane induces a lupus-like disease, which is milder than that induced in WT mice, showing significant differences in the inflammatory and autoimmune processes triggered by pristane. Extracellular vesicles (EV) are present in all body fluids. Shed by cells, their molecular make-up reflects that of their cell of origin and/or tissue pathological situation. The aim of this study was to analyze the protein composition, protein abundance, and functional clustering of EV released by peritoneal exudate cells (PECs) in the pristane experimental lupus model, to identify predictive or diagnostic biomarkers that might discriminate the autoimmune process in lupus from inflammatory reactions and/or normal physiological processes. In this study, thanks to an extensive proteomic analysis and powerful bioinformatics software, distinct EV subtypes were identified in the peritoneal exudates of pristane-treated mice: 1) small EV enriched in the tetraspanin CD63 and CD9, which are likely of exosomal origin; 2) small EV enriched in CD47 and CD9, which are also enriched in plasma-membrane, membrane-associated proteins, with an ectosomal origin; 3) small EV enriched in keratins, ECM proteins, complement/coagulation proteins, fibrin clot formation proteins, and endopetidase inhibitor proteins. This enrichment may have an inflammation-mediated mesothelial-to-mesenchymal transition origin, representing a protein corona on the surface of peritoneal exudate EV; 4) HDL-enriched lipoprotein particles. Quantitative proteomic analysis allowed us to identify an anti-inflammatory, Annexin A1-enriched pro-resolving, neutrophil protein signature, which was more prominent in EV from pristane-treated Cd38-/- mice, and quantitative differences in the protein cargo of the ECM-enriched EV from Cd38-/- vs WT mice. These differences are likely to be related with the distinct inflammatory outcome shown by Cd38-/- vs WT mice in response to pristane treatment. Our results demonstrate the power of a hypothesis-free and data-driven approach to transform the heterogeneity of the peritoneal exudate EV from pristane-treated mice in valuable information about the relative proportion of different EV in a given sample and to identify potential protein markers specific for the different small EV subtypes, in particular those proteins defining EV involved in the resolution phase of chronic inflammation.
- Published
- 2022
- Full Text
- View/download PDF
24. Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma
- Author
-
Noelia Maldonado-Pérez, María Tristán-Manzano, Pedro Justicia-Lirio, Elena Martínez-Planes, Pilar Muñoz, Kristina Pavlovic, Marina Cortijo-Gutiérrez, Carlos Blanco-Benítez, María Castella, Manel Juan, Mathias Wenes, Pedro Romero, Francisco J. Molina-Estévez, Concepción Marañón, Concha Herrera, Karim Benabdellah, and Francisco Martin
- Subjects
CAR-T cells ,lymphoma ,TCRKO ,CRISPR/Cas9 ,off-the-shelf ,safety ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Autologous T cells expressing the Chimeric Antigen Receptor (CAR) have been approved as advanced therapy medicinal products (ATMPs) against several hematological malignancies. However, the generation of patient-specific CAR-T products delays treatment and precludes standardization. Allogeneic off-the-shelf CAR-T cells are an alternative to simplify this complex and time-consuming process. Here we investigated safety and efficacy of knocking out the TCR molecule in ARI-0001 CAR-T cells, a second generation αCD19 CAR approved by the Spanish Agency of Medicines and Medical Devices (AEMPS) under the Hospital Exemption for treatment of patients older than 25 years with Relapsed/Refractory acute B cell lymphoblastic leukemia (B-ALL). We first analyzed the efficacy and safety issues that arise during disruption of the TCR gene using CRISPR/Cas9. We have shown that edition of TRAC locus in T cells using CRISPR as ribonuleorproteins allows a highly efficient TCR disruption (over 80%) without significant alterations on T cells phenotype and with an increased percentage of energetic mitochondria. However, we also found that efficient TCRKO can lead to on-target large and medium size deletions, indicating a potential safety risk of this procedure that needs monitoring. Importantly, TCR edition of ARI-0001 efficiently prevented allogeneic responses and did not detectably alter their phenotype, while maintaining a similar anti-tumor activity ex vivo and in vivo compared to unedited ARI-0001 CAR-T cells. In summary, we showed here that, although there are still some risks of genotoxicity due to genome editing, disruption of the TCR is a feasible strategy for the generation of functional allogeneic ARI-0001 CAR-T cells. We propose to further validate this protocol for the treatment of patients that do not fit the requirements for standard autologous CAR-T cells administration.
- Published
- 2022
- Full Text
- View/download PDF
25. Metabolic dyshomeostasis induced by SARS-CoV-2 structural proteins reveals immunological insights into viral olfactory interactions
- Author
-
Mercedes Lachén-Montes, Naroa Mendizuri, Karina Ausín, Miriam Echaide, Ester Blanco, Luisa Chocarro, María de Toro, David Escors, Joaquín Fernández-Irigoyen, Grazyna Kochan, and Enrique Santamaría
- Subjects
SARS-CoV-2 ,smell ,immune response ,proteomics ,transcriptomics ,bioinformatics ,Immunologic diseases. Allergy ,RC581-607 - Abstract
One of the most common symptoms in COVID-19 is a sudden loss of smell. SARS-CoV-2 has been detected in the olfactory bulb (OB) from animal models and sporadically in COVID-19 patients. To decipher the specific role over the SARS-CoV-2 proteome at olfactory level, we characterized the in-depth molecular imbalance induced by the expression of GFP-tagged SARS-CoV-2 structural proteins (M, N, E, S) on mouse OB cells. Transcriptomic and proteomic trajectories uncovered a widespread metabolic remodeling commonly converging in extracellular matrix organization, lipid metabolism and signaling by receptor tyrosine kinases. The molecular singularities and specific interactome expression modules were also characterized for each viral structural factor. The intracellular molecular imbalance induced by each SARS-CoV-2 structural protein was accompanied by differential activation dynamics in survival and immunological routes in parallel with a differentiated secretion profile of chemokines in OB cells. Machine learning through a proteotranscriptomic data integration uncovered TGF-beta signaling as a confluent activation node by the SARS-CoV-2 structural proteome. Taken together, these data provide important avenues for understanding the multifunctional immunomodulatory properties of SARS-CoV-2 M, N, S and E proteins beyond their intrinsic role in virion formation, deciphering mechanistic clues to the olfactory inflammation observed in COVID-19 patients.
- Published
- 2022
- Full Text
- View/download PDF
26. Protection against influenza-induced Acute Lung Injury (ALI) by enhanced induction of M2a macrophages: possible role of PPARγ/RXR ligands in IL-4-induced M2a macrophage differentiation
- Author
-
Archana Gopalakrishnan, John Joseph, Kari Ann Shirey, Achsah D. Keegan, Marina S. Boukhvalova, Stefanie N. Vogel, and Jorge C. G. Blanco
- Subjects
influenza ,M1 macrophage ,M2 macrophage ,PPARG ,Acute Lung Injury ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Many respiratory viruses cause lung damage that may evolve into acute lung injury (ALI), a cytokine storm, acute respiratory distress syndrome, and ultimately, death. Peroxisome proliferator activated receptor gamma (PPARγ), a member of the nuclear hormone receptor (NHR) family of transcription factors, regulates transcription by forming heterodimers with another NHR family member, Retinoid X Receptor (RXR). Each component of the heterodimer binds specific ligands that modify transcriptional capacity of the entire heterodimer by recruiting different co-activators/co-repressors. However, the role of PPARγ/RXR ligands in the context of influenza infection is not well understood. PPARγ is associated with macrophage differentiation to an anti-inflammatory M2 state. We show that mice lacking the IL-4Rα receptor, required for M2a macrophage differentiation, are more susceptible to mouse-adapted influenza (A/PR/8/34; “PR8”)-induced lethality. Mice lacking Ptgs2, that encodes COX-2, a key proinflammatory M1 macrophage mediator, are more resistant. Blocking the receptor for COX-2-induced Prostaglandin E2 (PGE2) was also protective. Treatment with pioglitazone (PGZ), a PPARγ ligand, increased survival from PR8 infection, decreased M1 macrophage gene expression, and increased PPARγ mRNA in lungs. Conversely, conditional knockout mice expressing PPARγ-deficient macrophages were significantly more sensitive to PR8-induced lethality. These findings were extended in cotton rats: PGZ blunted lung inflammation and M1 cytokine gene expression after challenge with non-adapted human influenza. To study mechanisms by which PPARγ/RXR transcription factors induce canonical M2a genes, WT mouse macrophages were treated with IL-4 in the absence or presence of rosiglitazone (RGZ; PPARγ ligand), LG100754 (LG; RXR ligand), or both. IL-4 dose-dependently induced M2a genes Arg1, Mrc1, Chil3, and Retnla. Treatment of macrophages with IL-4 and RGZ and/or LG differentially affected induction of Arg1 and Mrc1 vs. Chil3 and Retnla gene expression. In PPARγ-deficient macrophages, IL-4 alone failed to induce Arg1 and Mrc1 gene expression; however, concurrent treatment with LG or RGZ + LG enhanced IL-4-induced Arg1 and Mrc1 expression, but to a lower level than in WT macrophages, findings confirmed in the murine alveolar macrophage cell line, MH-S. These findings support a model in which PPARγ/RXR heterodimers control IL-4-induced M2a differentiation, and suggest that PPARγ/RXR agonists should be considered as important tools for clinical intervention against influenza-induced ALI.
- Published
- 2022
- Full Text
- View/download PDF
27. Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis
- Author
-
Sara Remuzgo-Martínez, Javier Rueda-Gotor, Verónica Pulito-Cueto, Raquel López-Mejías, Alfonso Corrales, Leticia Lera-Gómez, Raquel Pérez-Fernández, Virginia Portilla, Íñigo González-Mazón, Ricardo Blanco, Rosa Expósito, Cristina Mata, Javier Llorca, Vanesa Hernández-Hernández, Carlos Rodríguez-Lozano, Nuria Barbarroja, Rafaela Ortega-Castro, Esther Vicente, Cristina Fernández-Carballido, María Paz Martínez-Vidal, David Castro-Corredor, Joaquín Anino-Fernández, Diana Peiteado, Chamaida Plasencia-Rodríguez, Eva Galíndez-Agirregoikoa, María Luz García-Vivar, Nuria Vegas-Revenga, Irati Urionaguena, Oreste Gualillo, Juan Carlos Quevedo-Abeledo, Santos Castañeda, Iván Ferraz-Amaro, Miguel Á. González-Gay, and Fernanda Genre
- Subjects
irisin ,axial spondyloarthritis ,biomarker ,subclinical atherosclerosis ,cardiovascular risk ,disease severity ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionPatients with axial spondyloarthritis (axSpA) have a high disease burden mainly due to the rheumatic disease itself, and also exhibit accelerated atherosclerosis, that leads to a higher incidence of cardiovascular (CV) disease. Accordingly, the identification of biomarkers of CV risk and inflammation in axSpA patients is clinically relevant. In this sense, given the beneficial functions exerted by the adipomyokine irisin in processes related to CV disease and inflammation, our aim was to assess, for the first time, the role of irisin as a genetic and serological biomarker of subclinical atherosclerosis, CV risk and disease severity in axSpA patients.MethodsA large cohort of 725 Spanish patients with axSpA was included. Subclinical atherosclerosis (presence of plaques and abnormal carotid intima-media thickness values) was evaluated by carotid ultrasound. Four irisin polymorphisms (rs16835198 G/T, rs3480 A/G, rs726344 G/A, and rs1570569 G/T) were genotyped by TaqMan probes. Additionally, serum irisin levels were determined by ELISA.ResultsLow irisin levels were linked to the presence of plaques (p=0.002) and atherogenic index values ≥4 (p=0.01). Serum irisin were positively correlated with C-peptide levels (p2.1 (Odds Ratio (OR): 0.48 [0.28-0.83] and OR: 0.73 [0.57-0.92], respectively, p=0.01 in both cases). Additionally, the frequency of rs1570569 T allele was higher in these patients (OR: 1.46 [1.08-1.97], p=0.01). Furthermore, the GGGT haplotype was more frequent in patients with ASDAS values >2.1 (OR: 1.73 [1.13-2.66], p=0.01).ConclusionsOur results indicate that low serum irisin levels could be indicators of the presence of subclinical atherosclerosis, high CV risk and more severe disease in axSpA patients. In addition, irisin may also constitute a genetic biomarker of disease activity in axSpA.
- Published
- 2022
- Full Text
- View/download PDF
28. T-Follicular-Like CD8+ T Cell Responses in Chronic HIV Infection Are Associated With Virus Control and Antibody Isotype Switching to IgG
- Author
-
Luis Romero-Martín, Ferran Tarrés-Freixas, Núria Pedreño-López, Maria L. Rodríguez de la Concepción, Francesc Cunyat, Dennis Hartigan-O'Connor, Jorge Carrillo, Beatriz Mothe, Julià Blanco, Marta Ruiz-Riol, Christian Brander, and Alex Olvera
- Subjects
HIV ,humoral immune response ,human immunodeficiency virus (HIV) control ,T-follicular cytotoxic (Tfc) cells ,viral control ,Immunologic diseases. Allergy ,RC581-607 - Abstract
T cell responses are considered critical for the in vivo control of HIV, but the contribution of different T cell subsets to this control remains unclear. Using a boosted flow cytometric approach that is able to differentiate CD4+ and CD8+ T cell Th1/Tc1, Th2/Tc2, Th17/Tc17, Treg and Tfh/Tfc-like HIV-specific T cell populations, we identified CD8+ Tfc responses that were related to HIV plasma viral loads and associated with rate of antibody isotype class switching to IgG. This favorable balance towards IgG responses positively correlated with increased virus neutralization, higher avidity of neutralizing antibodies and more potent antibody-dependent cell cytotoxicity (ADCC) in PBMCs from HIV controllers compared to non-controllers. Our results identified the CD8+ Tfc-like T-cell response as a component of effective virus control which could possibly be exploited therapeutically.
- Published
- 2022
- Full Text
- View/download PDF
29. Exposing and Overcoming Limitations of Clinical Laboratory Tests in COVID-19 by Adding Immunological Parameters; A Retrospective Cohort Analysis and Pilot Study
- Author
-
Adrián Sánchez-Montalvá, Daniel Álvarez-Sierra, Mónica Martínez-Gallo, Janire Perurena-Prieto, Iria Arrese-Muñoz, Juan Carlos Ruiz-Rodríguez, Juan Espinosa-Pereiro, Pau Bosch-Nicolau, Xavier Martínez-Gómez, Andrés Antón, Ferran Martínez-Valle, Mar Riveiro-Barciela, Albert Blanco-Grau, Francisco Rodríguez-Frias, Pol Castellano-Escuder, Elisabet Poyatos-Canton, Jordi Bas-Minguet, Eva Martínez-Cáceres, Alex Sánchez-Pla, Coral Zurera-Egea, Aina Teniente-Serra, Manuel Hernández-González, Ricardo Pujol-Borrell, the “Hospital Vall d’Hebron Group for the study of COVID-19 immune profile”, Artur Llobell Uriel, Romina Dieli, Roger Colobran, Gemma Codina, Tomas Pumarola, Roser Ferrer, Vicente Cortina, Magda Campins, Isabel Ruiz, Nuria Fernaíndez, Esteban Ribera, Joan Roig, Ricardo Ferrer, Adolfo Ruiz-Sanmartín, Albert Selva, Moises Labrador, María José Soler Romeo, Jaume Ferrer, Eva Polverino, Antonio Alvarez, María Queralt Gorgas, Marta Miarons, Pere Soler-Palacin, Andrea Martin, Anna Suy, Maria Jose Buzón, Meritxell Genescà, Santiago Perez-Hoyos, and Miriam Mota-Foix
- Subjects
SARS-CoV-2 infection ,predictive risk-profile ,clinical laboratory tests ,cytokines ,chemokines ,acute phase reactants ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundTwo years since the onset of the COVID-19 pandemic no predictive algorithm has been generally adopted for clinical management and in most algorithms the contribution of laboratory variables is limited.ObjectivesTo measure the predictive performance of currently used clinical laboratory tests alone or combined with clinical variables and explore the predictive power of immunological tests adequate for clinical laboratories. Methods: Data from 2,600 COVID-19 patients of the first wave of the pandemic in the Barcelona area (exploratory cohort of 1,579, validation cohorts of 598 and 423 patients) including clinical parameters and laboratory tests were retrospectively collected. 28-day survival and maximal severity were the main outcomes considered in the multiparametric classical and machine learning statistical analysis. A pilot study was conducted in two subgroups (n=74 and n=41) measuring 17 cytokines and 27 lymphocyte phenotypes respectively.Findings1) Despite a strong association of clinical and laboratory variables with the outcomes in classical pairwise analysis, the contribution of laboratory tests to the combined prediction power was limited by redundancy. Laboratory variables reflected only two types of processes: inflammation and organ damage but none reflected the immune response, one major determinant of prognosis. 2) Eight of the thirty variables: age, comorbidity index, oxygen saturation to fraction of inspired oxygen ratio, neutrophil-lymphocyte ratio, C-reactive protein, aspartate aminotransferase/alanine aminotransferase ratio, fibrinogen, and glomerular filtration rate captured most of the combined statistical predictive power. 3) The interpretation of clinical and laboratory variables was moderately improved by grouping them in two categories i.e., inflammation related biomarkers and organ damage related biomarkers; Age and organ damage-related biomarker tests were the best predictors of survival, and inflammatory-related ones were the best predictors of severity. 4) The pilot study identified immunological tests (CXCL10, IL-6, IL-1RA and CCL2), that performed better than most currently used laboratory tests.ConclusionsLaboratory tests for clinical management of COVID 19 patients are valuable but limited predictors due to redundancy; this limitation could be overcome by adding immunological tests with independent predictive power. Understanding the limitations of tests in use would improve their interpretation and simplify clinical management but a systematic search for better immunological biomarkers is urgent and feasible.
- Published
- 2022
- Full Text
- View/download PDF
30. Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals
- Author
-
Edwards Pradenas, Maria Ubals, Víctor Urrea, Clara Suñer, Benjamin Trinité, Eva Riveira-Muñoz, Silvia Marfil, Carlos Ávila-Nieto, María Luisa Rodríguez de la Concepción, Ferran Tarrés-Freixas, Josep Laporte, Ester Ballana, Jorge Carrillo, Bonaventura Clotet, Oriol Mitjà, and Julià Blanco
- Subjects
COVID-19 ,seroconversion ,neutralizing antibodies ,viral load ,humoral response ,symptoms ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundEvidence on the determinants of the magnitude of humoral responses and neutralizing titers in individuals with mild COVID-19 is scarce.MethodsIn this cohort study of mild COVID-19 patients, we assessed viral load (VL) by RT-qPCR at two/three time points during acute infection, and anti-SARS-CoV-2 antibodies by ELISA and plasma neutralizing responses using a pseudovirus assay at day 60.ResultsSeventy-one individuals (65% female, median 42 years old) were recruited and grouped into high viral load (VL) >7.5 Log10 copies/mL (n=20), low, VL ≤7.5 Log10 copies/mL (n=22), or as Non-early seroconverters with a positive PCR (n=20), and healthy individuals with a negative PCR (n=9). Individuals with high or low VL showed similar titers of total neutralizing antibodies at day 60, irrespective of maximal VL or viral dynamics. Non-early seroconverters had lower antibody titers on day 60, albeit similar neutralizing activity as the groups with high or low VL. Longer symptom duration and older age were independently associated with increased humoral responses.ConclusionsIn mild SARS-CoV-2-infected individuals, the duration of symptoms and age (but not VL) contribute to higher humoral responses.
- Published
- 2022
- Full Text
- View/download PDF
31. Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology
- Author
-
José I. Fernández-Velasco, Enric Monreal, Jens Kuhle, Virginia Meca-Lallana, José Meca-Lallana, Guillermo Izquierdo, Celia Oreja-Guevara, Francisco Gascón-Giménez, Susana Sainz de la Maza, Paulette E. Walo-Delgado, Paloma Lapuente-Suanzes, Aleksandra Maceski, Eulalia Rodríguez-Martín, Ernesto Roldán, Noelia Villarrubia, Albert Saiz, Yolanda Blanco, Carolina Diaz-Pérez, Gabriel Valero-López, Judit Diaz-Diaz, Yolanda Aladro, Luis Brieva, Cristina Íñiguez, Inés González-Suárez, Luis A Rodríguez de Antonio, José M. García-Domínguez, Julia Sabin, Sara Llufriu, Jaime Masjuan, Lucienne Costa-Frossard, and Luisa M. Villar
- Subjects
multiple sclerosis ,demyelinating diseases ,ocrelizumab ,B cells ,biomarkers ,Immunologic diseases. Allergy ,RC581-607 - Abstract
ObjectiveTo ascertain the role of inflammation in the response to ocrelizumab in primary-progressive multiple sclerosis (PPMS).MethodsMulticenter prospective study including 69 patients with PPMS who initiated ocrelizumab treatment, classified according to baseline presence [Gd+, n=16] or absence [Gd-, n=53] of gadolinium-enhancing lesions in brain MRI. Ten Gd+ (62.5%) and 41 Gd- patients (77.4%) showed non-evidence of disease activity (NEDA) defined as no disability progression or new MRI lesions after 1 year of treatment. Blood immune cell subsets were characterized by flow cytometry, serum immunoglobulins by nephelometry, and serum neurofilament light-chains (sNfL) by SIMOA. Statistical analyses were corrected with the Bonferroni formula.ResultsMore than 60% of patients reached NEDA after a year of treatment, regardless of their baseline characteristics. In Gd+ patients, it associated with a low repopulation rate of inflammatory B cells accompanied by a reduction of sNfL values 6 months after their first ocrelizumab dose. Patients in Gd- group also had low B cell numbers and sNfL values 6 months after initiating treatment, independent of their treatment response. In these patients, NEDA status was associated with a tolerogenic remodeling of the T and innate immune cell compartments, and with a clear increase of serum IgA levels.ConclusionBaseline inflammation influences which immunological pathways predominate in patients with PPMS. Inflammatory B cells played a pivotal role in the Gd+ group and inflammatory T and innate immune cells in Gd- patients. B cell depletion can modulate both mechanisms.
- Published
- 2022
- Full Text
- View/download PDF
32. Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV
- Author
-
Javier Martínez-Sanz, Raquel Ron, Elena Moreno, Matilde Sánchez-Conde, Alfonso Muriel, Luis Fernando López Cortés, José Ramón Blanco, Juan Antonio Pineda, Álvaro Mena, Sonia Calzado Isbert, Santiago Moreno, and Sergio Serrano-Villar
- Subjects
HIV ,antiretroviral therapy ,dual therapy ,CD4/CD8 ratio ,integrase inhibitors ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundThe initiation of antiretroviral treatment based on a 2-drug regimen (2DR) with dolutegravir plus lamivudine has demonstrated non-inferior efficacy than dolutegravir-based three-drug regimens (3DR). We aimed to assess whether the treatment initiation with this 2DR has a different impact on the CD4/CD8 ratio recovery than INSTI-based 3DR.MethodsWe emulated a target trial using observational data from the Spanish HIV Research Network cohort (CoRIS). The outcomes of interest were the normalization of the CD4/CD8 ratio at 48 weeks using three different cutoffs: 0.5, 1.0, and 1.5. We matched each participant who started 2DR with up to four participants who received 3DR. Subsequently, we fitted generalized estimating equation (GEE) models and used the Kaplan–Meier method for survival curves.ResultsWe included 485, 805, and 924 participants for cutoffs of 0.5, 1.0, and 1.5, respectively. At 48 weeks, 45% of participants achieved a CD4/CD8 ratio >0.5, 15% achieved a ratio >1.0, and 6% achieved a ratio >1.5. GEE models yielded a similar risk of reaching a CD4/CD8 ratio >0.5 (OR 1.00, 95% CI 0.67 - 1.50), CD4/CD8 >1.0 (OR 1.03, 95% CI 0.68 - 1.58), and CD4/CD8 >1.5 (OR 0.86, 95% CI 0.48 - 1.54) between both treatment strategies. There were no differences between 2DR and 3DR in the incidence ratio of CD4/CD8 ratio normalization at 0.5, 1.0 and 1.5 cut-offs.ConclusionsIn this large cohort study in people with HIV, ART initiation with dolutegravir plus lamivudine vs. dolutegravir or bictegravir-based triple antiretroviral therapy showed no difference in the rates of CD4/CD8 normalization at 48 weeks.
- Published
- 2022
- Full Text
- View/download PDF
33. Comprehensive Flow Cytometry Profiling of the Immune System in COVID-19 Convalescent Individuals
- Author
-
Sergio Gil-Manso, Iria Miguens Blanco, Rocío López-Esteban, Diego Carbonell, Luis Andrés López-Fernández, Lori West, Rafael Correa-Rocha, and Marjorie Pion
- Subjects
COVID-19 ,immune system ,flow cytometry ,unsupervised algorithms ,immune dysregulation ,Immunologic diseases. Allergy ,RC581-607 - Abstract
SARS-CoV-2 has infected more than 200 million people worldwide, with more than 4 million associated deaths. Although more than 80% of infected people develop asymptomatic or mild COVID-19, SARS-CoV-2 can induce a profound dysregulation of the immune system. Therefore, it is important to investigate whether clinically recovered individuals present immune sequelae. The potential presence of a long-term dysregulation of the immune system could constitute a risk factor for re-infection and the development of other pathologies. Here, we performed a deep analysis of the immune system in 35 COVID-19 recovered individuals previously infected with SARS-CoV-2 compared to 16 healthy donors, by flow cytometry. Samples from COVID-19 individuals were analysed from 12 days to 305 days post-infection. We observed that, 10 months post-infection, recovered COVID-19 patients presented alterations in the values of some T-cell, B-cell, and innate cell subsets compared to healthy controls. Moreover, we found in recovered COVID-19 individuals increased levels of circulating follicular helper type 1 (cTfh1), plasmablast/plasma cells, and follicular dendritic cells (foDC), which could indicate that the Tfh-B-foDC axis might be functional to produce specific immunoglobulins 10 months post-infection. The presence of this axis and the immune system alterations could constitute prognosis markers and could play an important role in potential re-infection or the presence of long-term symptoms in some individuals.
- Published
- 2022
- Full Text
- View/download PDF
34. The Chemokine Receptor CCR5 Links Memory CD4+ T Cell Metabolism to T Cell Antigen Receptor Nanoclustering
- Author
-
Raquel Blanco, Marta Gómez de Cedrón, Laura Gámez-Reche, Ana Martín-Leal, Alicia González-Martín, Rosa A. Lacalle, Ana Ramírez de Molina, and Santos Mañes
- Subjects
memory CD4+ T cells ,efector CD4+ T cells ,metabolic reprogramming ,chemokine signaling ,CCR5 ,BCL6 ,Immunologic diseases. Allergy ,RC581-607 - Abstract
The inhibition of anabolic pathways, such as aerobic glycolysis, is a metabolic cornerstone of memory T cell differentiation and function. However, the signals that hamper these anabolic pathways are not completely known. Recent evidence pinpoints the chemokine receptor CCR5 as an important player in CD4+ T cell memory responses by regulating T cell antigen receptor (TCR) nanoclustering in an antigen-independent manner. This paper reports that CCR5 specifically restrains aerobic glycolysis in memory-like CD4+ T cells, but not in effector CD4+ T cells. CCR5-deficient memory CD4+ T cells thus show an abnormally high glycolytic/oxidative metabolism ratio. No CCR5-dependent change in glucose uptake nor in the expression of the main glucose transporters was detected in any of the examined cell types, although CCR5-deficient memory cells did show increased expression of the hexokinase 2 and pyruvate kinase M2 isoforms, plus the concomitant downregulation of Bcl-6, a transcriptional repressor of these key glycolytic enzymes. Further, the TCR nanoclustering defects observed in CCR5-deficient antigen-experienced CD4+ T cells were partially reversed by incubation with 2-deoxyglucose (2-DG), suggesting a link between inhibition of the glycolytic pathway and TCR nanoscopic organization. Indeed, the treatment of CCR5-deficient lymphoblasts with 2-DG enhanced IL-2 production after antigen re-stimulation. These results identify CCR5 as an important regulator of the metabolic fitness of memory CD4+ T cells, and reveal an unexpected link between T cell metabolism and TCR organization with potential influence on the response of memory T cells upon antigen re-encounter.
- Published
- 2021
- Full Text
- View/download PDF
35. BpOmpW Antigen Stimulates the Necessary Protective T-Cell Responses Against Melioidosis
- Author
-
Julen Tomás-Cortázar, Lorenzo Bossi, Conor Quinn, Catherine J. Reynolds, David K. Butler, Niamh Corcoran, Maitiú Ó Murchú, Eve McMahon, Mahavir Singh, Patpong Rongkard, Juan Anguita, Alfonso Blanco, Susanna J. Dunachie, Daniel Altmann, Rosemary J. Boyton, Johan Arnold, Severine Giltaire, and Siobhán McClean
- Subjects
melioidosis ,vaccine ,Burkholderia pseudomallei ,T-cell responses ,IFN-γ ,type 2 diabetes ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Melioidosis is a potentially fatal bacterial disease caused by Burkholderia pseudomallei and is estimated to cause 89,000 deaths per year in endemic areas of Southeast Asia and Northern Australia. People with diabetes mellitus are most at risk of melioidosis, with a 12-fold increased susceptibility for severe disease. Interferon gamma (IFN-γ) responses from CD4 and CD8 T cells, but also from natural killer (NK) and natural killer T (NKT) cells, are necessary to eliminate the pathogen. We previously reported that immunization with B. pseudomallei OmpW (BpOmpW antigen) protected mice from lethal B. pseudomallei challenge for up to 81 days. Elucidating the immune correlates of protection of the protective BpOmpW vaccine is an essential step prior to clinical trials. Thus, we immunized either non-insulin-resistant C57BL/6J mice or an insulin-resistant C57BL/6J mouse model of type 2 diabetes (T2D) with a single dose of BpOmpW. BpOmpW induced strong antibody responses, stimulated effector CD4+ and CD8+ T cells and CD4+ CD25+ Foxp3+ regulatory T cells, and produced higher IFN-γ responses in CD4+, CD8+, NK, and NKT cells in non-insulin-resistant mice. The T-cell responses of insulin-resistant mice to BpOmpW were comparable to those of non-insulin-resistant mice. In addition, as a precursor to its evaluation in human studies, humanized HLA-DR and HLA-DQ (human leukocyte antigen DR and DQ isotypes, respectively) transgenic mice elicited IFN-γ recall responses in an enzyme-linked immune absorbent spot (ELISpot)-based study. Moreover, human donor peripheral blood mononuclear cells (PBMCs) exposed to BpOmpW for 7 days showed T-cell proliferation. Finally, plasma from melioidosis survivors with diabetes recognized our BpOmpW vaccine antigen. Overall, the range of approaches used strongly indicated that BpOmpW elicits the necessary immune responses to combat melioidosis and bring this vaccine closer to clinical trials.
- Published
- 2021
- Full Text
- View/download PDF
36. Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial
- Author
-
Lorna Leal, Elvira Couto, Sonsoles Sánchez-Palomino, Núria Climent, Irene Fernández, Laia Miralles, Yolanda Romero, Tania González, Maria José Maleno, Blanca Paño, Judit Pich, Carlos Nicolau, José Maria Gatell, Montserrat Plana, Felipe García, the DCV3-RISVAC04 Study Group, Carmen Hurtado, Laura Burunat, Joan Albert Arnaiz, Rafael Salvador, Elisabet Farré, Berta Torres, Constanza Lucero, Montserrat Laguno, María Martínez-Rebollar, Ana González-Cordón, John Rojas, Alexy Inciarte, Lorena de la Mora, Josep Mallolas, Esteban Martínez, José Luis Blanco, Unai Perpiñá, Josep Canals, Raquel Martín, Florencia Echeverry, Cristina Xufré, Cristina Rovira, Marta Sala, and Amparo Tricas
- Subjects
therapeutic vaccine ,dendritic cell ,interferon alpha ,combined strategy ,ATI ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionFunctional cure has been proposed as an alternative to lifelong antiretroviral therapy and therapeutic vaccines represent one of the most promising approaches.Materials and MethodsWe conducted a double-blind randomized placebo-controlled clinical trial to evaluate the safety, immunogenicity, and effect on viral dynamics of a therapeutic vaccine produced with monocyte-derived dendritic cells (MD-DC) loaded with a high dose of heat-inactivated autologous (HIA) HIV-1 in combination with pegylated interferon alpha 2a (IFNα-2a) in people with chronic HIV-1.ResultsTwenty-nine male individuals on successful ART and with CD4+ ≥450 cells/mm3 were randomized 1:1:1:1 to receive three ultrasound-guided inguinal intranodal immunizations, one every 2 weeks: (1) vaccine ~107 MD-DC pulsed with HIA-HIV-1 (1010 HIV RNA copies) (n = 8); (2) vaccine plus three doses of 180 mcg IFNα-2a at weeks 4–6 (n = 6); (3) placebo = saline (n = 7); and (4) placebo plus three doses of 180 mcg IFNα-2a (n = 8). Thereafter, treatment was interrupted (ATI). Vaccines, IFNα-2a, and the administration procedures were safe and well tolerated. All patients’ viral load rebounded during the 12-week ATI period. According to groups, changes in viral set-point between pre-ART and during ATI were not significant. When comparing all groups, there was a tendency in changes in viral set-point between the vaccine group vs. vaccine + IFNα-2a group (>0.5log10p = 0.05). HIV-1-specific T-cell responses (IFN-ƴ Elispot) were higher at baseline in placebo than in the vaccine group (2,259 ± 535 vs. 900 ± 200 SFC/106 PBMC, p = 0.028). A significant difference in the change of specific T-cell responses was only observed at week 4 between vaccine and placebo groups (694 ± 327 vs. 1,718 ± 282 SFC/106 PBMC, p = 0.04). No effect on T-cell responses or changes in viral reservoir were observed after INFα-2a administration.DiscussionResults from this study show that intranodally administered DC therapeutic vaccine in combination with IFNα-2a was safe and well-tolerated but had a minimal impact on viral dynamics in HIV-1 chronic infected participants.Clinical Trial Registration(www.ClinicalTrials.gov), identifier NCT02767193
- Published
- 2021
- Full Text
- View/download PDF
37. Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge
- Author
-
Yaiza Senent, Susana Inogés, Ascensión López-Díaz de Cerio, Andres Blanco, Arantxa Campo, Francisco Carmona-Torre, Patricia Sunsundegui, Antonio González-Martín, Daniel Ajona, Marcin Okrój, Felipe Prósper, Ruben Pio, José Ramón Yuste, and Beatriz Tavira
- Subjects
innate immunity ,complement system ,C5a ,COVID-19 ,SARS-CoV-2 ,respiratory symptoms ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Evidence supports a role of complement anaphylatoxin C5a in the pathophysiology of COVID-19. However, information about the evolution and impact of C5a levels after hospital discharge is lacking. We analyzed the association between circulating C5a levels and the clinical evolution of hospitalized patients infected with SARS-CoV-2. Serum C5a levels were determined in 32 hospitalized and 17 non-hospitalized patients from Clinica Universidad de Navarra. One hundred and eighty eight serial samples were collected during the hospitalization stay and up to three months during the follow-up. Median C5a levels were 27.71 ng/ml (25th to 75th percentile: 19.35-34.96) for samples collected during hospitalization, versus 16.76 ng/ml (12.90-25.08) for samples collected during the follow-up (p
- Published
- 2021
- Full Text
- View/download PDF
38. Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort
- Author
-
Maria J. Pons, Barbara Ymaña, Ana Mayanga-Herrera, Yolanda Sáenz, Lydia Alvarez-Erviti, Salyoc Tapia-Rojas, Roxana Gamarra, Amanda B. Blanco, Gemma Moncunill, and Manuel F. Ugarte-Gil
- Subjects
COVID-19 ,cytokine ,prognosis ,SARS-CoV-2 IgG ,proinflammatory ,biomarkers ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Cytokines, chemokines and growth factors present different expression profiles related to the prognosis of COVID-19. We analyzed clinical parameters and assessed the expression of these biomarkers in patients with different disease severity in a hospitalized Peruvian cohort to determine those associated with worse prognosis. We measured anti-spike IgG antibodies by ELISA and 30 cytokines by quantitative suspension array technology in 123 sera samples. We analyzed differences between patients with moderate, severe and fatal COVID-19 by logistic regression at baseline and in longitudinal samples. Significant differences were found among the clinical parameters: hemoglobin, neutrophils, lymphocytes and C-reactive protein (CRP), creatinine and D-dimer levels. Higher anti-spike IgG antibody concentrations were associated to fatal patient outcomes. At hospitalization, IL-10, IL-6, MIP-1α, GM-CSF, MCP-1, IL-15, IL-5, IL1RA, TNFα and IL-8 levels were already increased in fatal patients´ group. Meanwhile, multivariable analysis revealed that increased GM-CSF, MCP-1, IL-15, and IL-8 values were associated with fatal outcomes. Moreover, longitudinal analysis identified IL-6 and MCP-1 as the main risk factors related to mortality in hospitalized COVID-19 patients. In this Peruvian cohort we identified and validated biomarkers related to COVID-19 outcomes. Further studies are needed to identify novel criteria for stratification of SARS-CoV-2 infected patients at hospital entry. BackgroundIn the most severe forms of SARS-CoV-2 infection, large numbers of innate and adaptive immune cells become activated and begin to produce pro-inflammatory cytokines, establishing an exacerbated feedback loop of inflammation.MethodsA total of 55 patients with laboratory-confirmed COVID-19 admitted to the Hospital Nacional Guillermo Almenara Irigoyen in Lima, Peru were enrolled during August-October 2020. Of these, 21 had moderate disease, 24 severe diseases and 10 died. We measured 30 cytokines and chemokines by quantitative suspension array technology and anti-spike IgG antibodies using a commercial ELISA. We evaluated these parameters in peripheral blood every 2-5 days until patient discharge or death. Patient information and clinical parameters related were obtained from the respective clinical histories.ResultsThe frequency of obesity differed among the 3 groups, being most frequent in patients who died. There were also significant differences in clinical parameters: hemoglobin, segmented neutrophils, lymphocytes,C-reactive protein, creatinine and D-dimer levels. Greater anti-spike IgG antibody concentrations were associated to fatal outcomes. In univariate analyses, higher baseline concentrations of IL-6, MIP-1α, GM-CSF, MCP-1, IL-15, IL-5, IL1RA, TNFα, IL-8 and IL-12p70 correlated with severity, while multivariable analysis showed that increased concentrations in 4 biomarkers (GM-CSF, MCP-1, IL-15, IL-8) were associated with fatal outcomes. Longitudinal analysis showed IL-6 (hazard ratio [HR] 6.81, 95% confidence interval [CI] 1.6-28.7) and MCP-1 (HR 4.61, 95%CI 1.1-19.1) to be related to mortality in hospitalized COVID-19 patients.ConclusionsCytokine, chemokine and growth factor profiles were identified and validated related to severity and outcomes of COVID-19. Our findings may be useful to identify novel criteria for COVID-19 patient stratification at hospital entry.
- Published
- 2021
- Full Text
- View/download PDF
39. Whole-Blood Mitochondrial DNA Copies Are Associated With the Prognosis of Acute Respiratory Distress Syndrome After Sepsis
- Author
-
Tamara Hernández-Beeftink, Beatriz Guillen-Guio, Héctor Rodríguez-Pérez, Itahisa Marcelino-Rodríguez, Jose M. Lorenzo-Salazar, Almudena Corrales, Miryam Prieto-González, Aurelio Rodríguez-Pérez, Demetrio Carriedo, Jesús Blanco, Alfonso Ambrós, Elena González-Higueras, Nancy G. Casanova, Manuel González-Garay, Elena Espinosa, Arturo Muriel, David Domínguez, Abelardo García de Lorenzo, José M. Añón, Marina Soro, Javier Belda, Joe G. N. Garcia, Jesús Villar, and Carlos Flores
- Subjects
ARDS ,mitochondria ,DAMPs ,whole blood ,mtDNA ,survival ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Acute respiratory distress syndrome (ARDS) is an inflammatory process of the lungs that develops primarily in response to pulmonary or systemic sepsis, resulting in a disproportionate death toll in intensive care units (ICUs). Given its role as a critical activator of the inflammatory and innate immune responses, previous studies have reported that an increase of circulating cell-free mitochondrial DNA (mtDNA) is a biomarker for fatal outcome in the ICU. Here we analyzed the association of whole-blood mtDNA (wb-mtDNA) copies with 28-day survival from sepsis and sepsis-associated ARDS. We analyzed mtDNA data from 687 peripheral whole-blood samples within 24 h of sepsis diagnosis from unrelated Spanish patients with sepsis (264 with ARDS) included in the GEN-SEP study. The wb-mtDNA copies were obtained from the array intensities of selected probes, with 100% identity with mtDNA and with the largest number of mismatches with the nuclear sequences, and normalized across the individual-probe intensities. We used Cox regression models for testing the association with 28-day survival. We observed that wb-mtDNA copies were significantly associated with 28-day survival in ARDS patients (hazard ratio = 3.65, 95% confidence interval = 1.39–9.59, p = 0.009) but not in non-ARDS patients. Our findings support that wb-mtDNA copies at sepsis diagnosis could be considered an early prognostic biomarker in sepsis-associated ARDS patients. Future studies will be needed to evaluate the mechanistic links of this observation with the pathogenesis of ARDS.
- Published
- 2021
- Full Text
- View/download PDF
40. Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management
- Author
-
Marta López-Nevado, Luis I. González-Granado, Raquel Ruiz-García, Daniel Pleguezuelo, Oscar Cabrera-Marante, Nerea Salmón, Pilar Blanco-Lobo, Nerea Domínguez-Pinilla, Rebeca Rodríguez-Pena, Elena Sebastián, Jaime Cruz-Rojo, Peter Olbrich, Jesús Ruiz-Contreras, Estela Paz-Artal, Olaf Neth, and Luis M. Allende
- Subjects
ALPS ,ALPS-like ,autoimmunity ,lymphoproliferation ,malignancy ,immune dysregulation ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Primary immune regulatory disorders (PIRD) are associated with autoimmunity, autoinflammation and/or dysregulation of lymphocyte homeostasis. Autoimmune lymphoproliferative syndrome (ALPS) is a PIRD due to an apoptotic defect in Fas-FasL pathway and characterized by benign and chronic lymphoproliferation, autoimmunity and increased risk of lymphoma. Clinical manifestations and typical laboratory biomarkers of ALPS have also been found in patients with a gene defect out of the Fas-FasL pathway (ALPS-like disorders). Following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA), we identified more than 600 patients suffering from 24 distinct genetic defects described in the literature with an autoimmune lymphoproliferative phenotype (ALPS-like syndromes) corresponding to phenocopies of primary immunodeficiency (PID) (NRAS, KRAS), susceptibility to EBV (MAGT1, PRKCD, XIAP, SH2D1A, RASGRP1, TNFRSF9), antibody deficiency (PIK3CD gain of function (GOF), PIK3R1 loss of function (LOF), CARD11 GOF), regulatory T-cells defects (CTLA4, LRBA, STAT3 GOF, IL2RA, IL2RB, DEF6), combined immunodeficiencies (ITK, STK4), defects in intrinsic and innate immunity and predisposition to infection (STAT1 GOF, IL12RB1) and autoimmunity/autoinflammation (ADA2, TNFAIP3,TPP2, TET2). CTLA4 and LRBA patients correspond around to 50% of total ALPS-like cases. However, only 100% of CTLA4, PRKCD, TET2 and NRAS/KRAS reported patients had an ALPS-like presentation, while the autoimmunity and lymphoproliferation combination resulted rare in other genetic defects. Recurrent infections, skin lesions, enteropathy and malignancy are the most common clinical manifestations. Some approaches available for the immunological study and identification of ALPS-like patients through flow cytometry and ALPS biomarkers are provided in this work. Protein expression assays for NKG2D, XIAP, SAP, CTLA4 and LRBA deficiencies and functional studies of AKT, STAT1 and STAT3 phosphorylation, are showed as useful tests. Patients suspected to suffer from one of these disorders require rapid and correct diagnosis allowing initiation of tailored specific therapeutic strategies and monitoring thereby improving the prognosis and their quality of life.
- Published
- 2021
- Full Text
- View/download PDF
41. Retinoic Acid Induces Functionally Suppressive Foxp3+RORγt+ T Cells In Vitro
- Author
-
Mónica Martínez-Blanco, Daniel Lozano-Ojalvo, Leticia Pérez-Rodríguez, Sara Benedé, Elena Molina, and Rosina López-Fandiño
- Subjects
food allergy ,regulatory T cells ,Il-6 ,Il17 ,retinoic acid ,Th17 ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionCD4+ T cells with regulatory function co-expressing Foxp3 and RORγt are linked to the development of oral tolerance towards innocuous food antigens in mice. This study aimed to discern the role played by IL-6 and retinoic acid (RA) in the in vitro generation of Foxp3+RORγt+ T cells and to investigate whether such cells have suppressive properties.MethodsCD4+CD25- T cells isolated from the spleen of BALB/c mice, were stimulated in the presence of IL-2 alone or together with TFG-β and different concentrations of IL-6 and/or RA. Percentage of Foxp3+, RORγt+, IL-17+, Foxp3+RORγt-, Foxp3+RORγt+, and Foxp3-RORγt+ T cells within the total CD4+ T cell population, production of cytokines (IL-10 and IL-17A) and gene expression (Foxp3, Rorc, Tgfb1, Il6, Il10, and Il17) were assessed at different time points. The phenotype and ability of cells generated from CD4+CD44-CD62L+ cells in the presence of RA to suppress effector T cell proliferation was assessed.ResultsTGF-β plus IL-6 induced the generation of Foxp3+ and double positive Foxp3+RORγt+ T cells to a higher extent than TGF-β alone at the beginning of the incubation period, although expression of Foxp3 subsequently declined. RA, added to TGF-β, increased Foxp3 and Rorc expression and Foxp3 and RORγt transcription and promoted the differentiation of Foxp3+RORγt- and Foxp3+RORγt+ cells that expressed and secreted IL-17. Foxp3+ T cells generated in vitro in presence of RA were functionally suppressive.ConclusionsUnder the influence of IL-2 and TGF-β, suppressive Foxp3+RORγt+ T cells that express and secrete IL-17 can be produced in vitro and RA further contributes to stabilize this phenotype.
- Published
- 2021
- Full Text
- View/download PDF
42. CD38 Deficiency Ameliorates Chronic Graft-Versus-Host Disease Murine Lupus via a B-Cell-Dependent Mechanism
- Author
-
África Martínez-Blanco, Marilú Domínguez-Pantoja, María Botía-Sánchez, Sonia Pérez-Cabrera, Nerea Bello-Iglesias, Paula Carrillo-Rodríguez, Natividad Martin-Morales, Antonio Lario-Simón, María M. Pérez-Sánchez-Cañete, Laura Montosa-Hidalgo, Salvador Guerrero-Fernández, Victoria M. Longobardo-Polanco, Sandra Redondo-Sánchez, Alberto Cornet-Gomez, María Torres-Sáez, Ana Fernández-Ibáñez, Laura Terrón-Camero, Eduardo Andrés-León, Francisco O’Valle, Ramón Merino, Mercedes Zubiaur, and Jaime Sancho
- Subjects
CD38 ,cGVHD lupus-like ,T-bet+ B cells ,anti-ssDNA antibodies ,GC B cells ,STAT1 ,Immunologic diseases. Allergy ,RC581-607 - Abstract
The absence of the mouse cell surface receptor CD38 in Cd38−/− mice suggests that this receptor acts as a positive regulator of inflammatory and autoimmune responses. Here, we report that, in the context of the chronic graft-versus-host disease (cGVHD) lupus inducible model, the transfer of B6.C-H2bm12/KhEg(bm12) spleen cells into co-isogenic Cd38−/− B6 mice causes milder lupus-like autoimmunity with lower levels of anti-ssDNA autoantibodies than the transfer of bm12 spleen cells into WT B6 mice. In addition, significantly lower percentages of Tfh cells, as well as GC B cells, plasma cells, and T-bet+CD11chi B cells, were observed in Cd38−/− mice than in WT mice, while the expansion of Treg cells and Tfr cells was normal, suggesting that the ability of Cd38−/− B cells to respond to allogeneic help from bm12 CD4+ T cells is greatly diminished. The frequencies of T-bet+CD11chi B cells, which are considered the precursors of the autoantibody-secreting cells, correlate with anti-ssDNA autoantibody serum levels, IL-27, and sCD40L. Proteomics profiling of the spleens from WT cGVHD mice reflects a STAT1-driven type I IFN signature, which is absent in Cd38−/− cGVHD mice. Kidney, spleen, and liver inflammation was mild and resolved faster in Cd38−/− cGVHD mice than in WT cGVHD mice. We conclude that CD38 in B cells functions as a modulator receptor that controls autoimmune responses.
- Published
- 2021
- Full Text
- View/download PDF
43. Low-Density Neutrophils in Healthy Individuals Display a Mature Primed Phenotype
- Author
-
Carlos Blanco-Camarillo, Omar Rafael Alemán, and Carlos Rosales
- Subjects
neutrophil ,inflammation ,phagocytosis ,neutrophil extracellular traps ,reactive oxygen species ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Neutrophils are the most abundant leukocytes in human peripheral blood, comprising about 70% of all leukocytes. They are regarded as the first line of defense of the innate immune system, but neutrophils have also the ability of regulating the adaptive immune response. Recently, However, multiple phenotypes and functional states of neutrophils have been reported, particularly in inflammation, autoimmunity, and cancer. One possible subtype of neutrophils, the so-called low-density neutrophils (LDN) is found among mononuclear cells (MNC), monocytes and lymphocytes, after separating the leukocytes from blood by density gradient centrifugation. LDN increase in numbers during several pathological conditions. However, LDN present in healthy conditions have not been investigated further. Therefore, in order to confirm the presence of LDN in blood of healthy individuals and to explore some of their cellular functions, neutrophils and MNC were isolated by density gradient centrifugation. Purified neutrophils were further characterized by multicolor flow cytometry (FACS) and then, using the same FACS parameters cells in the MNC fraction were analyzed. Within the MNC, LDN were consistently found. These LDN had a normal mature neutrophil morphology and displayed a CD10+, CD11b+, CD14low, CD15high, CD16bhigh, CD62L+, CD66b+, and CXCR4+ phenotype. These LDN had an enhanced reactive oxygen species (ROS) production and increased phagocytic capacity and were able to produce neutrophil extracellular traps (NET) similarly to neutrophils. These data confirm the presence of a small number of LDN is blood of healthy individuals and suggest that these LDN represent mature cells with a primed phenotype.
- Published
- 2021
- Full Text
- View/download PDF
44. Targeting TLR4 Signaling to Blunt Viral-Mediated Acute Lung Injury
- Author
-
Kari Ann Shirey, Jorge C. G. Blanco, and Stefanie N. Vogel
- Subjects
TLR4 ,influenza ,ALI ,viruses ,HMGB1 ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Respiratory viral infections have been a long-standing global burden ranging from seasonal recurrences to the unexpected pandemics. The yearly hospitalizations from seasonal viruses such as influenza can fluctuate greatly depending on the circulating strain(s) and the congruency with the predicted strains used for the yearly vaccine formulation, which often are not predicted accurately. While antiviral agents are available against influenza, efficacy is limited due to a temporal disconnect between the time of infection and symptom development and viral resistance. Uncontrolled, influenza infections can lead to a severe inflammatory response initiated by pathogen-associated molecular patterns (PAMPs) or host-derived danger-associated molecular patterns (DAMPs) that ultimately signal through pattern recognition receptors (PRRs). Overall, these pathogen-host interactions result in a local cytokine storm leading to acute lung injury (ALI) or the more severe acute respiratory distress syndrome (ARDS) with concomitant systemic involvement and more severe, life threatening consequences. In addition to traditional antiviral treatments, blocking the host’s innate immune response may provide a more viable approach to combat these infectious pathogens. The SARS-CoV-2 pandemic illustrates a critical need for novel treatments to counteract the ALI and ARDS that has caused the deaths of millions worldwide. This review will examine how antagonizing TLR4 signaling has been effective experimentally in ameliorating ALI and lethal infection in challenge models triggered not only by influenza, but also by other ALI-inducing viruses.
- Published
- 2021
- Full Text
- View/download PDF
45. Identifying Bacterial and Host Factors Involved in the Interaction of Mycobacterium bovis with the Bovine Innate Immune Cells
- Author
-
Federico Carlos Blanco, María José Gravisaco, María Mercedes Bigi, Elizabeth Andrea García, Cecilia Marquez, Mike McNeil, Mary Jackson, and Fabiana Bigi
- Subjects
innate immune response ,Mycobacterium bovis ,NK cells ,ESAT-6 ,bovine tuberculosis ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Bovine tuberculosis is an important animal and zoonotic disease caused by Mycobacterium bovis. The innate immune response is the first line of defense against pathogens and is also crucial for the development of an efficient adaptive immune response. In this study we used an in vitro co-culture model of antigen presenting cells (APC) and autologous lymphocytes derived from peripheral blood mononuclear cells to identify the cell populations and immune mediators that participate in the development of an efficient innate response capable of controlling the intracellular replication of M. bovis. After M. bovis infection, bovine immune cell cultures displayed upregulated levels of iNOS, IL-22 and IFN-γ and the induction of the innate immune response was dependent on the presence of differentiated APC. Among the analyzed M. bovis isolates, only a live virulent M. bovis isolate induced an efficient innate immune response, which was increased upon stimulation of cell co-cultures with the M. bovis culture supernatant. Moreover, we demonstrated that an allelic variation of the early secreted protein ESAT-6 (ESAT6 T63A) expressed in the virulent strain is involved in this increased innate immune response. These results highlight the relevance of the compounds secreted by live M. bovis as well as the variability among the assessed M. bovis strains to induce an efficient innate immune response.
- Published
- 2021
- Full Text
- View/download PDF
46. TLR2 Regulates Mast Cell IL-6 and IL-13 Production During Listeria monocytogenes Infection
- Author
-
Rodolfo Soria-Castro, Ángel R. Alfaro-Doblado, Gloria Rodríguez-López, Marcia Campillo-Navarro, Yatsiri G. Meneses-Preza, Adrian Galán-Salinas, Violeta Alvarez-Jimenez, Juan C. Yam-Puc, Rosario Munguía-Fuentes, Adriana Domínguez-Flores, Sergio Estrada-Parra, Sonia M. Pérez-Tapia, Alma D. Chávez-Blanco, and Rommel Chacón-Salinas
- Subjects
mast cell ,Listeria monocytogenes ,toll like receptor-2 ,IL-6 ,IL-13 ,p38 ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Listeria monocytogenes (L.m) is efficiently controlled by several cells of the innate immunity, including the Mast Cell (MC). MC is activated by L.m inducing its degranulation, cytokine production and microbicidal mechanisms. TLR2 is required for the optimal control of L.m infection by different cells of the immune system. However, little is known about the MC receptors involved in recognizing this bacterium and whether these interactions mediate MC activation. In this study, we analyzed whether TLR2 is involved in mediating different MC activation responses during L.m infection. We found that despite MC were infected with L.m, they were able to clear the bacterial load. In addition, MC degranulated and produced ROS, TNF-α, IL-1β, IL-6, IL-13 and MCP-1 in response to bacterial infection. Interestingly, L.m induced the activation of signaling proteins: ERK, p38 and NF-κB. When TLR2 was blocked, L.m endocytosis, bactericidal activity, ROS production and mast cell degranulation were not affected. Interestingly, only IL-6 and IL-13 production were affected when TLR2 was inhibited in response to L.m infection. Furthermore, p38 activation depended on TLR2, but not ERK or NF-κB activation. These results indicate that TLR2 mediates only some MC activation pathways during L.m infection, mainly those related to IL-6 and IL-13 production.
- Published
- 2021
- Full Text
- View/download PDF
47. Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients
- Author
-
Esperanza Martín-Sánchez, Juan José Garcés, Catarina Maia, Susana Inogés, Ascensión López-Díaz de Cerio, Francisco Carmona-Torre, Marta Marin-Oto, Félix Alegre, Elvira Molano, Mirian Fernandez-Alonso, Cristina Perez, Cirino Botta, Aintzane Zabaleta, Ana Belen Alcaide, Manuel F. Landecho, Marta Rua, Teresa Pérez-Warnisher, Laura Blanco, Sarai Sarvide, Amaia Vilas-Zornoza, Diego Alignani, Cristina Moreno, Iñigo Pineda, Miguel Sogbe, Josepmaria Argemi, Bruno Paiva, and José Ramón Yuste
- Subjects
COVID-19 ,SARS-CoV-2 ,flow cytometry ,lymphopenia ,outcome ,survival ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Information on the immunopathobiology of coronavirus disease 2019 (COVID-19) is rapidly increasing; however, there remains a need to identify immune features predictive of fatal outcome. This large-scale study characterized immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection using multidimensional flow cytometry, with the aim of identifying high-risk immune biomarkers. Holistic and unbiased analyses of 17 immune cell-types were conducted on 1,075 peripheral blood samples obtained from 868 COVID-19 patients and on samples from 24 patients presenting with non-SARS-CoV-2 infections and 36 healthy donors. Immune profiles of COVID-19 patients were significantly different from those of age-matched healthy donors but generally similar to those of patients with non-SARS-CoV-2 infections. Unsupervised clustering analysis revealed three immunotypes during SARS-CoV-2 infection; immunotype 1 (14% of patients) was characterized by significantly lower percentages of all immune cell-types except neutrophils and circulating plasma cells, and was significantly associated with severe disease. Reduced B-cell percentage was most strongly associated with risk of death. On multivariate analysis incorporating age and comorbidities, B-cell and non-classical monocyte percentages were independent prognostic factors for survival in training (n=513) and validation (n=355) cohorts. Therefore, reduced percentages of B-cells and non-classical monocytes are high-risk immune biomarkers for risk-stratification of COVID-19 patients.
- Published
- 2021
- Full Text
- View/download PDF
48. In Patients With Obesity, the Number of Adipose Tissue Mast Cells Is Significantly Lower in Subjects With Type 2 Diabetes
- Author
-
David Lopez-Perez, Anaïs Redruello-Romero, Jesús Garcia-Rubio, Carlos Arana, Luis A. Garcia-Escudero, Francisco Tamayo, Jose D. Puentes-Pardo, Sara Moreno-SanJuan, Javier Salmeron, Armando Blanco, Julio Galvez, Josefa Leon, and Ángel Carazo
- Subjects
mast cell ,T2D ,adipose tissue ,obesity ,flow cytometry ,angiogenesis ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Type 2 diabetes (T2D) is a rising global health problem mainly caused by obesity and a sedentary lifestyle. In healthy individuals, white adipose tissue (WAT) has a relevant homeostatic role in glucose metabolism, energy storage, and endocrine signaling. Mast cells contribute to these functions promoting WAT angiogenesis and adipogenesis. In patients with T2D, inflammation dramatically impacts WAT functioning, which results in the recruitment of several leukocytes, including monocytes, that enhance this inflammation. Accordingly, the macrophages population rises as the WAT inflammation increases during the T2D status worsening. Since mast cell progenitors cannot arrive at WAT, the amount of WAT mast cells depends on how the new microenvironment affects progenitor and differentiated mast cells. Here, we employed a flow cytometry-based approach to analyze the number of mast cells from omental white adipose tissue (o-WAT) and subcutaneous white adipose tissue (s-WAT) in a cohort of 100 patients with obesity. Additionally, we measured the number of mast cell progenitors in a subcohort of 15 patients. The cohort was divided in three groups: non-T2D, pre-T2D, and T2D. Importantly, patients with T2D have a mild condition (HbA1c
- Published
- 2021
- Full Text
- View/download PDF
49. Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients
- Author
-
Stéphanie Bibert, Nicolas Guex, Joao Lourenco, Thomas Brahier, Matthaios Papadimitriou-Olivgeris, Lauro Damonti, Oriol Manuel, Robin Liechti, Lou Götz, Jonathan Tschopp, Mathieu Quinodoz, Peter Vollenweider, Jean-Luc Pagani, Mauro Oddo, Olivier Hügli, Frédéric Lamoth, Véronique Erard, Cathy Voide, Mauro Delorenzi, Nathalie Rufer, Fabio Candotti, Carlo Rivolta, Noémie Boillat-Blanco, Pierre-Yves Bochud, the RegCOVID Study Group, Bochud Pierre-Yves, Desgranges Florian, Filippidis Paraskevas, Guéry Benoit, Haefliger David, Kampouri Eleftheria-Evdokia, Manuel Oriol, Munting Aline, Pagani Jean-Luc, Papadimitriou-Olivgeris Matthaios, Regina Jean, Rochat-Stettler Laurence, Suttels Veronique, Tadini Eliana, Tschopp Jonathan, Van Singer Mathias, Viala Benjamin, and Vollenweider Peter
- Subjects
COVID-19 ,SARS-CoV-2 ,influenza ,whole blood transcriptome ,RNA-sequencing ,immune profiling ,Immunologic diseases. Allergy ,RC581-607 - Abstract
The reason why most individuals with COVID-19 have relatively limited symptoms while other develop respiratory distress with life-threatening complications remains unknown. Increasing evidence suggests that COVID-19 associated adverse outcomes mainly rely on dysregulated immunity. Here, we compared transcriptomic profiles of blood cells from 103 patients with different severity levels of COVID-19 with that of 27 healthy and 22 influenza-infected individuals. Data provided a complete overview of SARS-CoV-2-induced immune signature, including a dramatic defect in IFN responses, a reduction of toxicity-related molecules in NK cells, an increased degranulation of neutrophils, a dysregulation of T cells, a dramatic increase in B cell function and immunoglobulin production, as well as an important over-expression of genes involved in metabolism and cell cycle in patients infected with SARS-CoV-2 compared to those infected with influenza viruses. These features also differed according to COVID-19 severity. Overall and specific gene expression patterns across groups can be visualized on an interactive website (https://bix.unil.ch/covid/). Collectively, these transcriptomic host responses to SARS-CoV-2 infection are discussed in the context of current studies, thereby improving our understanding of COVID-19 pathogenesis and shaping the severity level of COVID-19.
- Published
- 2021
- Full Text
- View/download PDF
50. Corrigendum: The Role of Nucleases and Nucleic Acid Editing Enzymes in the Regulation of Self-Nucleic Acid Sensing
- Author
-
Pauline Santa, Anne Garreau, Lee Serpas, Amandine Ferriere, Patrick Blanco, Chetna Soni, and Vanja Sisirak
- Subjects
DNases ,RNases ,systemic lupus erythematosus ,DNA sensing ,RNA sensing ,interferonopathies ,Immunologic diseases. Allergy ,RC581-607 - Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.